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Summary
Background Cancer survival varies widely between countries. The CONCORD study provides survival estimates for 
1·9 million adults (aged 15–99 years) diagnosed with a ﬁ rst, primary, invasive cancer of the breast (women), colon, 
rectum, or prostate during 1990–94 and followed up to 1999, by use of individual tumour records from 101 population-
based cancer registries in 31 countries on ﬁ ve continents. This is, to our knowledge, the ﬁ rst worldwide analysis of 
cancer survival, with standard quality-control procedures and identical analytic methods for all datasets. 
Methods To compensate for wide international diﬀ erences in general population (background) mortality by age, sex, 
country, region, calendar period, and (in the USA) ethnic origin, we estimated relative survival, the ratio of survival 
noted in the patients with cancer, and the survival that would have been expected had they been subject only to the 
background mortality rates. 2800 life tables were constructed. Survival estimates were also adjusted for diﬀ erences in 
the age structure of populations of patients with cancer.
Findings Global variation in cancer survival was very wide. 5-year relative survival for breast, colorectal, and prostate 
cancer was generally higher in North America, Australia, Japan, and northern, western, and southern Europe, and 
lower in Algeria, Brazil, and eastern Europe. CONCORD has provided the ﬁ rst opportunity to estimate cancer survival 
in 11 states in USA covered by the National Program of Cancer Registries (NPCR), and the study covers 42% of the US 
population, four-fold more than previously available. Cancer survival in black men and women was systematically and 
substantially lower than in white men and women in all 16 states and six metropolitan areas included. Relative survival 
for all ethnicities combined was 2–4% lower in states covered by NPCR than in areas covered by the Surveillance 
Epidemiology and End Results (SEER) Program. Age-standardised relative survival by use of the appropriate race-
speciﬁ c and state-speciﬁ c life tables was up to 2% lower for breast cancer and up to 5% lower for prostate cancer than 
with the census-derived national life tables used by the SEER Program. These diﬀ erences in population coverage and 
analytical method have both contributed to the survival deﬁ cit noted between Europe and the USA, from which only 
SEER data have been available until now.
Interpretation Until now, direct comparisons of cancer survival between high-income and low-income countries have 
not generally been available. The information provided here might therefore be a useful stimulus for change. The 
ﬁ ndings should eventually facilitate joint assessment of international trends in incidence, survival, and mortality as 
indicators of cancer control.
Funding Centers for Disease Control and Prevention (Atlanta, GA, USA), Department of Health (London, UK), Cancer 
Research UK (London, UK). 
Introduction
International comparisons of population-based cancer 
survival have been rare,1–5 but large and unexplained diﬀ er-
ences in survival have been reported for many cancers 
from individual studies and cancer registries in Europe and 
North America.6 For example, 5-year relative survival for 
women diagnosed with breast cancer during 1985–89 was 
73% in Europe (weighted mean for 17 countries)7 and 84% 
in the USA.8 The CONCORD study provides a systematic 
comparison of survival between Europe and North 
America,9–16 extended to countries in all other continents.
The ﬁ rst international comparison of cancer survival, 
published in 1964,17 was a study of patients diagnosed with 
one of 15 common cancers in Denmark, England, Finland, 
France, Norway, Sweden, and the USA, mainly during 
1945–54. It was the ﬁ rst study in which relative survival 
techniques, ﬁ rst described in the 1950s,18–20 were used to 
correct the survival estimates for diﬀ erences in background 
mortality between participant countries. The ﬁ ndings are 
mainly of historical interest, but survival in the USA 
(represented by Connecticut) was generally higher than in 
the European countries.
Cancer survival is known to vary between the regions of 
the USA covered by the US National Cancer Institute’s 
(NCI) Surveillance, Epidemiology and End Results (SEER) 
Program,21 but the range of survival in Europe is much 
wider. Furthermore, survival from breast cancer during 
1985–94 was higher in each of the nine SEER areas than in 
any of the 22 countries participating in the European study 
of cancer survival (EUROCARE).7,22 The diﬀ erences were 
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often more marked in elderly patients:9 for several cancers, 
5-year survival for patients diagnosed aged 75 years or older 
during the 1990s was nearly 20% higher in the USA than 
in Europe.23
The CONCORD study began in 1999 as an extension of 
the EUROCARE-3 study, then just starting. EUROCARE has 
published systematic comparisons of survival for most adult 
and childhood cancers in Europe since 1995.24 The ﬁ rst 
EURO CARE study involved patients diagnosed in 1978–84 
in 12 countries;25 EUROCARE-2 covered patients diag-
nosed during 1985–89 in 17 countries,26 and EURO CARE-3 
involved 22 countries, with patients diag nosed in 1990–94 
and followed up to 1999.27,28 More recently, EURO CARE-4 
has included patients diagnosed in 23 coun tries dur ing all 
or part of 1995–2002 and followed up to 2003.29,30
CONCORD was originally designed to assess the survival 
of adults (aged 15–99 years) diagnosed with cancer of the 
breast (women), colorectum, or prostate during 1990–94 in 
Europe and the USA, using population-based data and 
standardised quality control, and with identical analysis for 
all datasets, adjusted for diﬀ erences in general population 
(background) mortality by country, region, race, and calen-
dar period, and also for diﬀ erences in the age structure of 
patient populations. CONCORD also enables comparison 
of cancer survival between ﬁ ve states and four metropolitan 
areas in the USA covered by the SEER Program (SEER-9) 
and 11 states covered by the Centers for Disease Control 
and Prevention’s (CDC) National Program of Cancer 
Registries (NPCR). It also provides a wider comparison of 
cancer survival between black and white patients in the 
USA than has previously been possible.
CONCORD includes data from one or more countries 
on all ﬁ ve continents. To our knowledge, it is the ﬁ rst 
attempt at a global comparison of cancer survival.
Methods
Cancer registries
In 1999, we identiﬁ ed at international cancer meetings in 
Atlanta (USA) and Lisbon (Portugal), and from published 
studies, population-based cancer registries that had pub-
lished survival data and were operational during 1990–99. 
Registries that had met the quality criteria for inclusion in 
Cancer Incidence in Five Continents (volume VII, 1988–92)31 
were eligible. We obtained data from 19 other registries. 
Most had met comparable criteria, such as those in the 
EURO CARE-3 study (patients diagnosed during 1990–94 
with follow-up to 1999).28 North American regist ries were 
eligible if they had met the standards required for Cancer 
Incidence in North America, 1991–95,32 and could provide 
com plete follow-up to the end of 1999. In total, we identiﬁ ed 
112 registries, but 11 were withdrawn or excluded: no re-
sponse (one); withdrawal for legal reasons (one); incom-
plete registration before 1995 (four); follow-up activity 
stopped be fore 1999 (two); data not supplied by the 
September, 2005 deadline (three).
A pilot study of 50 registries in 2000 obtained a 100% 
response. All registries were able to provide data for 
patients diagnosed during all or part of the period 1990–94, 
and had access to various data sources to obtain follow-up 
information for all patients for at least 5 years or to the end 
of 1999. After further recruitment, a detailed questionnaire 
was obtained for 100 of the 101 registries ﬁ nally included in 
the analyses, covering data deﬁ nitions and methods of 
operation, including data collection, coding of tumour site, 
morphology, behaviour, and stage at diagnosis, tracing of 
registered patients to ascertain their vital status, and 
linkage between data on the incident tumour and data on 
subsequent death or loss to follow-up. The procedures and 
deﬁ nitions used, the stated quality and completeness of 
data on the registration of incident cancers, and of the 
follow-up of those patients over the next 5 years, were 
deemed adequate to attempt cancer-survival analysis, 
subject to central quality control of the data. The pilot study 
conﬁ rmed the feasibility of the CONCORD protocol33 and 
the active support of cancer registries for wider international 
comparisons of cancer survival. The questionnaire and 
detailed ﬁ ndings are available online.34
Data sources
Anonymised individual tumour records were obtained from 
population-based cancer registries in all ﬁ ve contin ents, as 
deﬁ ned on UN guidelines:35 Africa, America (Central and 
South, including the Caribbean), America (North), Asia, 
Europe, and Oceania (table 1 and webﬁ gure 1). We retained 
Hawaii (USA) with North America rather than Oceania.
Africa was represented by a single cancer registry, for the 
wilaya (département, or state) of Sétif (Algeria).
Central and South America, including the Caribbean, 
were represented by the national cancer registry of Cuba 
and two regional registries in Brazil: the Goiânia (Goiás 
state) registry is one of 20 registries in state capitals, 
whereas the Campinas (São Paulo state) registry is the only 
one in Brazil that is not in a state capital.
Data from North America include ﬁ ve of the seven 
largest provinces in Canada (British Columbia, Manitoba, 
Nova Scotia, Ontario, and Saskatchewan). Data for the USA 
came from 22 registries covering 16 states (California, 
Colorado, Connecticut, Florida, Hawaii, Idaho, Iowa, Louis-
iana, Michigan, Nebraska, New Jersey, New Mexico, New 
York State, Rhode Island, Utah, and Wyoming) and six 
metro politan areas (Atlanta, GA, Los Angeles, CA, San 
Fran cisco, CA, Detroit, MI, New York City, NY, and Seattle, 
WA).
Population-based cancer registries in the USA receive 
sup port from either or both of the two federal cancer-
surveillance programmes, the NCI’s SEER Program and 
the CDC’s NPCR.36 As of 1990, the SEER Program in cluded 
nine population-based cancer registries covering some 
10% of the US population (SEER-9): the states of 
Connecticut, Hawaii, Iowa, New Mexico, and Utah, and the 
metropolitan areas of Atlanta, GA, Detroit, MI, San 
Francisco, CA, and Seattle, WA. The Los Angeles cancer 
registry be came a SEER registry in 1992, but we opted to 
retain it with the NPCR data, so that the SEER grouping 
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we used was identical with that for which SEER data had 
been published in the past (SEER-9). The NPCR at the 
CDC began more recently, and this is the ﬁ rst cancer-
survival analysis for 11 states: California, Colorado, Florida, 
Idaho, Louisiana, Michigan, Nebraska, New Jersey, New 







Breast Colon Rectum Colorectum Prostate Total 
Women Men Women Men Women Men Women
Africa
Algeria (Sétif) 1 104 561 4·2 180 10 14 30 30 40 44 36 300
America (Central and South)
Brazilian registries 1 795 387 1·2 806 130 194 50 69 180 263 474 1723
Campinas 870 380 0·6 175 61 82 .. .. .. .. 149 467
Goiânia 925 007 0·6 631 69 112 50 69 119 181 325 1256
Cuba 10 754 868 100·0 6461 1083 1516 674 734 1757 2250 4341 14 809
South American 
registries
12 550 255 ·· 7267 1213 1710 724 803 1937 2513 4815 16 532
America (North)
Canadian registries 16 474 543 58·1 44 620 13 989 13 819 6272 4220 20 261 18 039 45 999 128 919
British Columbia 3 131 700 11·0 9141 2223 2178 625 412 2848 2590 11 496 26 075
Manitoba 1 109 998 3·9 2932 954 957 556 343 1510 1300 3761 9503
Nova Scotia 918 000 3·2 2316 771 829 ·· ·· ·· ·· 2243 6159
Ontario 10 298 801 36·3 27 389 9214 9069 4613 3154 13 827 12 223 25 310 78 749
Saskatchewan 1 016 044 3·6 2842 827 786 478 311 1305 1097 3189 8433
US registries 108 775 729 42·4 324 551 89 673 96 186 40 149 32 774 129 822 128 960 356 881 940 214
Atlanta,† GA 2 315 961 0·9 5747 1215 1473 474 496 1689 1969 6406 15 811
California 30 974 659 12·1 85 143 21 384 22 351 9999 8172 31 383 30 523 95 707 242 756
   Los Angeles,  CA 9 055 424 ·· 22 587 5741 6136 2659 2233 8400 8369 25 789 65 145
   San Francisco, CA 3 805 588 ·· 12 321 3165 3375 1463 1194 4628 4569 12 733 34 251
Colorado 3 495 939 1·4 9117 2084 2183 944 751 3028 2934 11 433 26 512
Connecticut 3 300 712 1·3 11 335 3112 3299 1458 1128 4570 4427 11 357 31 689
Florida 13 650 553 5·3 46 065 14 845 15 007 6007 4790 20 852 19 797 64 256 150 970
Hawaii 1 158 613 0·5 2857 986 808 508 279 1494 1087 3482 8920
Idaho 1 071 685 0·4 2689 676 681 331 239 1007 920 3899 8515
Iowa 2 818 401 1·1 9133 2776 3532 1267 989 4043 4521 10 743 28 440
Louisiana 4 293 003 1·7 11 204 3302 3780 1374 1186 4676 4966 13 059 33 905
Michigan 9 479 065 3·7 31 183 8821 9323 3791 3162 12 612 12 485 23 705 79 985
   Detroit, MI 3 969 304 ·· 12 247 3223 3534 1499 1213 4722 4747 17 162 38 878
Nebraska 1 611 687 0·6 5242 1625 1801 776 544 2401 2345 6828 16 816
New Jersey 7 880 508 3·1 27 125 8110 8670 3694 3091 11 804 11 761 29 877 80 567
New Mexico 1 595 442 0·6 3796 901 892 436 323 1337 1215 5393 11 741
New York State 18 246 653 7·1 55 404 15 191 17 426 6936 5889 22 127 23 315 47 096 147 942
   New York City 7 322 564 ·· 21 644 5821 7048 2335 2253 8156 9301 16 770 55 871
Rhode Island 1 012 581 0·4 3466 1113 1280 477 440 1590 1720 3449 10 225
Seattle,† WA 3 567 217 1·4 10 451 2415 2577 1168 893 3583 3470 12 818 30 322
Utah 1 836 799 0·7 3506 866 805 393 293 1259 1098 5779 11 642
Wyoming 466 251 0·2 1088 251 298 116 109 367 407 1594 3456
North American 
registries
125 250 272 44·0 369 171 103 662 110 005 46 421 36 994 150 083 146 999 402 880 1 069 133
Asia
Japanese registries 10 819 997 8·7 7179 5469 4588 3510 2248 8979 6836 1691 24 685
Fukui 827 000 0·7 840 738 709 477 310 1215 1019 325 3399
Osaka 8 734 516 7·0 5112 3337 2593 2075 1283 5412 3876 920 15 320
Yamagata 1 258 481 1·0 1227 1394 1286 958 655 2352 1941 446 5966
(Continues on next page)
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Breast Colon Rectum Colorectum Prostate Total 
Women Men Women Men Women Men Women
(Continued from previous page)
Europe
Austria (Tirol) 624 939 8·0 1559 416 483 261 237 677 720 1432 4388
Czech Republic ( West 
Bohemia)
861 000 8·3 1543 672 601 681 416 1353 1017 693 4606
Denmark 5 145 160 100·0 14 686 3954 4822 3308 2495 7262 7317 6503 35 768
Estonia 1 562 468 100·0 2205 598 845 479 553 1077 1398 1143 5823
Finland 5 070 000 100·0 12 214 1907 2639 1687 1561 3594 4200 7544 27 552
French registries 3 098 526 5·6 6359 1675 1544 1164 876 2839 2420 2909 14 527
Bas-Rhin 954 710 1·8 2591 848 730 522 379 1370 1109 1626 6696
Calvados 618 353 1·1 1640 440 448 345 309 785 757 1283 4465
Côte d’Or 507 147 0·9 791 387 366 297 188 684 554 .. 2029
Isère 1 018 316 1·8 1337 .. .. .. ·· .. .. .. 1337
Germany (Saarland) 1 067 027 1·3 2957 1035 1237 712 656 1747 1893 1610 8207
Iceland 254 960 100·0 504 125 128 37 47 162 175 493 1334
Ireland 3 609 000 100·0 1513 587 534 382 224 969 758 1062 4302
Italian registries 8 944 772 15·3 26 403 8713 8672 4743 3887 13 456 12 559 10 671 63 089
Ferrara 355 479 0·6 1321 488 486 200 158 688 644 438 3091
Genoa 695 981 1·3 2571 892 894 442 380 1334 1274 1122 6301
Latina 468 865 0·8 657 199 182 135 84 334 266 197 1454
Macerata 281 537 0·5 629 296 283 168 119 464 402 435 1930
Modena 602 570 0·5 1887 641 654 361 275 1002 929 810 4628
Parma 391 237 0·7 1318 480 410 256 204 736 614 456 3124
Ragusa 140 537 0·5 513 159 171 123 82 282 253 227 1275
Romagna 604 488 0·8 1347 498 549 226 226 724 775 740 3586
Sassari 469 570 0·8 591 143 128 126 62 269 190 198 1248
Turin 996 443 1·8 3009 868 904 500 457 1368 1361 1030 6768
Tuscany 1 167 687 2·1 3807 1420 1446 854 702 2274 2148 1797 10 026
Varese 793 378 1·4 2400 691 710 410 344 1101 1054 803 5358
Veneto 1 977 000 3·5 6 353 1938 1855 942 794 2880 2649 2418 14 300
Malta 365 000 100·0 359 76 73 53 31 129 104 111 703
Netherlands registries 5 158 472 34·3 15 862 2418 2791 1471 1271 3889 4062 5353 29 166
Amsterdam 2 620 000 17·4 7509 1764 2117 1020 946 2784 3063 4171 17 527
Netherlands (North) 1 602 661 10·6 5999 .. .. ·· ·· .. .. .. 5999
Netherlands (South) 935 811 6·3 2354 654 674 451 325 1105 999 1182 5640
Norway 4 245 180 100·0 9193 3590 4136 2536 2048 6126 6184 9841 31 344
Polish registries 2 373 190 6·1 4220 1080 1152 827 773 1907 1925 1159 9211
Cracow 747 985 1·9 1205 240 243 203 168 443 411 253 2312
Warsaw 1 625 205 4·2 3015 840 909 624 605 1464 1514 906 6899
Portugal (South) 1 145 000 11·4 1219 364 355 327 236 691 591 344 2845
Slovakia 5 297 774 100·0 6079 2572 2126 2646 1815 5218 3941 2821 18 059
Slovenia 2 072 000 100·0 3327 914 898 1025 851 1939 1749 160 8175
Spanish registries 5 566 140 14·4 9744 3439 2934 2502 1613 5941 4547 4273 24 505
Basque Country 2 097 000 5·4 3816 1321 1027 1057 589 2378 1616 1721 9531
Granada 787 898 2·0 879 299 255 219 152 518 407 .. 1804
Mallorca 582 655 1·5 1143 447 394 296 213 743 607 617 3110
Murcia 1 036 966 2·8 1485 505 512 397 330 902 842 643 3872
Navarra 520 300 1·3 1229 404 304 249 167 653 471 688 3041
Tarragona 541 321 1·4 1192 463 442 284 162 747 604 604 3147
(Continues on next page)
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Survival estimates reported from the SEER Program 
have until now been the only population-based cancer 
survival data from the USA.21,37 We wanted to compare 
survival between the areas covered by registries in the 
NPCR and the SEER Program during 1990–94. We received 
separate datasets from Detroit, MI, San Francisco, CA 
(SEER registries), and Los Angeles, CA (NPCR), and these 
were included in the respective totals for SEER and NPCR. 
However, the data from these metropolitan areas could not 
be separately identiﬁ ed in the state-wide datasets we 
received from California and Michigan, therefore, the non-
metropolitan data for those states could not be included 
with the other NPCR data. Data from all nine SEER 
registries were available.38
Survival in the SEER-9 areas was therefore compared with 







Breast Colon Rectum Colorectum Prostate Total 
Women Men Women Men Women Men Women
(Continued from previous page)
Sweden 8 826 939 100·0 24 170 6112 6685 4401 3578 10 513 10 263 24 041 68 987
Swiss registries 1 758 249 25·8 4847 .. .. ·· ·· .. .. .. 4847
Basel 429 104 6·3 1365 .. .. ·· ·· .. .. .. 1365
Geneva 381 492 5·6 1275 .. .. ·· ·· .. .. .. 1275
Graubunden-Glarus 210 485 3·1 544 .. .. ·· ·· .. .. .. 544
St Gallen-Appenzell 483 801 7·1 1 027 .. .. ·· ·· .. .. .. 1027
Valais 253 367 3·7 636 .. .. ·· ·· .. .. .. 636
UK 58 984 046 ·· 154 867 41 499 45 729 30 600 22 556 72 099 68 285 78 608 373 859
England (national) 49 310 000 100·0 129 703 33 983 37 334 25 618 18 780 59 601 56 114 66 181 311 599
   East Anglia 2 089 000 4·2 6330 1820 2060 1245 954 3065 3014 3897 16 306
   Mersey 2 412 000 4·9 6561 1932 2080 1425 1069 3357 3149 3242 16 309
   Oxford 2 582 000 5·2 7458 1737 1934 1193 929 2930 2863 3612 16 863
   South Thames 6 756 000 13·7 17 002 3880 4689 2824 2328 6704 7017 8232 38 955
   South West 3 320 000 6·7 19 203 5630 6215 3869 2917 9499 9132 11 766 49 600
   Trent 4 745 000 9·6 13 360 3523 3793 3045 2087 6568 5880 6774 32 582
   West Midlands 5 278 000 10·7 13 561 4397 4482 3272 2066 7669 6548 7315 35 093
   Yorkshire 3 698 000 7·5 9 473 2599 2910 2121 1574 4720 4484 5165 23 842
   English registries 30 880 000 62·5 92 948 25 518 28 163 18 994 13 924 44 512 42 087 50 003 229 550
Northern Ireland 1 648 960 100·0 1527 562 576 328 224 890 800 888 4105
Scotland 5 100 086 100·0 14 254 4441 5089 2671 2124 7112 7213 6855 35 434
Wales 2 925 000 100·0 9383 2513 2730 1983 1428 4496 4158 4684 22 721
European registries 126 029 842 ·· 303 830 81 746 88 384 59 842 45 724 141 588 134 108 161 771 741 297
Oceania
Australia 18 071 422 100·0 41 090 15 200 15 098 9911 6904 25 111 22 002 42 890 131 093
Australian Capital 
Territory
304 371 1·7 548 180 160 99 78 279 238 414 1479
New South Wales 6 133 913 33·9 14 382 5358 5066 3478 2354 8836 7420 15 507 46 145
Northern Territory 178 062 1·0 165 46 41 41 20 87 61 78 391
Queensland 3 252 245 18·0 7052 2783 2743 1619 998 4402 3741 7468 22 663
Southern Australia 1 473 966 8·2 3688 1323 1335 937 734 2260 2069 4228 12 245
Tasmania 472 971 2·6 1081 474 453 242 171 716 624 1321 3742
Victoria 4 521 392 25·0 10 583 3865 4103 2683 1978 6548 6081 9826 33 038
Western Australia 1 734 502 9·6 3591 1171 1197 812 571 1983 1768 4048 11 390
CONCORD
CONCORD total 293 826 349 ·· 728 717 207 300 219 799 120 438 92 703 327 738 312 502 614 083 1 983 040
*Some registries provided data for shorter periods, ie, 4 years: Campinas,  Macerata,  Granada (1991–94); 3 years: Isère (1990–92) , Portugal (1991–93),  Sétif , Sassari 
(1992–94); 2 years: Malta, Northern Ireland (1993–94); 1 year: Ireland (1994). †No state-wide data available for this city. Where a registry did not provide data for a given 
cancer, cell entries for numbers of patients and survival estimates are left blank. National percentages are derived from the raw data and can diﬀ er from the sum of regional 
percentages because of rounding. Row totals avoid double counting of colon and rectal tumours, also shown in the table as colon and rectum combined. 
Table 1: Population coverage and number of adults (aged 15–99 years) diagnosed with cancer of the breast, colon, rectum, or prostate during 
1990–94* and included in the analyses: continent, country, and region
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NPCR: Colorado, Florida, Idaho, Los Angeles, CA, Louis-
iana, Nebraska, New Jersey, New York, Rhode Island, and 
Wyoming. For this comparison, data from the non-metro-
politan areas of California and Michigan were ex cluded to 
ensure that the two sets of data were mutually exclusive.
In Asia, Japan was represented by three of the prefectural 
(state) registries: Fukui, Osaka, and Yamagata.
In Europe, the 53 cancer registries that contributed data 
to EUROCARE-328 on cancers of the breast, colon, rectum, 
or prostate all participated in the CONCORD study. Six 
other registries also provided data: two national registries 
(Northern Ireland and Ireland) and four regional registries 
from the Netherlands (North) and Switzerland (Grau-
bunden-Glarus, St Gallen-Appenzell, Valais). As in the 
EURO CARE study, the UK is considered as its four con-
stitu ent countries (England, Scotland, Wales, Northern 
Ireland), each of which has a national registry. In England, 
both the national cancer registry and eight of the regional 
cancer registries submitted datasets.
Oceania was represented by the national cancer registry 
of Australia, with data from each of the eight population-
based state or territorial registries.
Quality control
Procedures used in the EUROCARE-3 study were applied 
to all datasets. Tumour records were supplied with the ana-
tomical site coded to the ninth revision of the International 
Classiﬁ cation of Diseases (ICD-939) for four index tumours: 
cancers of the breast (women) (ICD-9 174.0–174.9), colon 
(153.0–153.9), rectum (including the anus, 154.0–154.9), 
and prostate (185). Tumour morph ology and behaviour 
were coded to the ﬁ rst or second revision of ICD-Oncology 
(ICD-O,40 ICD-O-241). Only invasive malignant tumours 
(behaviour code 3) were included. Patients with an index 
tumour had sometimes been registered with another 
malignancy, either before or after the index tumour. Data 
on those other cancers in index patients were also sub-
mitted. Only the ﬁ rst, primary, invasive, malignant tumour 
diagnosed in each patient was retained for analysis. 
Patients registered with a malignant neoplasm before the 
index tumour were excluded, although non-melanoma 
skin cancer was not counted as a previous tumour for this 
purpose. Bilateral breast cancers and multiple colon 
cancers were included as a single tumour if synchronous; 
otherwise, only the earliest tumour was considered. The 
duration of survival was taken from the date of diagnosis 
of the index tumour until death from any cause, or until 
the patient was censored from the analysis as alive, either 
at loss to follow-up or after Dec 31, 1999, whichever came 
ﬁ rst; any subsequent tumour occurring in the same patient 
during that period was ignored.
Standard quality-control routines, based on those devel-
oped by the International Agency for Research on Cancer,42 
were applied to each tumour record. Records with invalid 
codes, impossible sequences of dates, or improbable com-
binations of tumour site and morphology were re turned to 
the registry for checking. Usually, the registry provided a 
correction or an explanation. Corrected tumour records 
were checked again: those which still had missing, invalid 
or inconsistent values for sex, site, morphology, or dates 
were ﬂ agged as major errors and excluded from analysis. 
Records for which an unlikely combination of age, site and 
morphology had nonetheless been conﬁ rmed as correct 
were ﬂ agged as minor errors, and included in the analyses. 
Details of the approach have been published else where.43 
Detailed quality-control ﬁ ndings are available online.34
Follow-up
All registries used more than one mechanism of follow-up 
to ascertain the vital status (alive, dead, emigrated, lost to 
follow-up) and the date of the last vital status for each 
registered patient. The mechanisms varied between 
countries, usually linkage between the registry’s database 
and a variety of other data sources, especially the national 
index of deaths. Secure linkage of a tumour record and a 
record of death, based on a set of identiﬁ ers such as name, 
sex, date of birth, and personal identity number, enabled 
the registry to update the tumour record accordingly. Direct 
contact with the patient or their family to establish vital 
status was unusual, although home visits by registry staﬀ  
were done in Algeria. Enquiries to the patient’s primary 
care physician or hospital consultant were frequently used. 
A wide variety of administrative data bases was also used, 
such as social insurance, health insurance, motor vehicle 
records, drivers’ licences, hospital discharge records, 
national primary-care databases, electoral registers (those 
eligible to vote), and voter registration records (those who 
voted in the last election). The presence of a person’s record 
in such administrative databases on a given date is taken 
as evidence that the person was alive on that date. This is 
subject to administrative error (failure to remove in timely 
fashion the record of a person known to be dead) and fraud 
(by someone seeking to retain access to beneﬁ ts received 
by the deceased), but in most instances the risks are small. 
If coverage of the databases was known to be high, and 
especially if a person was present in more than one such 
database, the risk of error decreased further.
In the USA, a match to an administrative database might 
show that an event occurred during a certain quarter of a year 
(eg, an insurance claim paid, a licence renewed), but the 
exact date might not be known; the date of last vital status 
was then set to the ﬁ rst day of the quarter, ie, Jan 1, April 1, 
July 1, Sept 1. This approach can give rise to irregu lar distri-
 bu tions of the day of last known vital status, but it is a 
conservative approach to establishing when patients were 
last known to be alive, because patients are censored from 
sur vival analysis on the latest of any such dates in the 
record.
The proportion of patients not known to be dead and for 
whom the registry could not be certain that the date of last 
vital status was at least 5 years after diagnosis was less than 
1% overall. The proportion was often zero (follow-up for at 
least 5 years was established for every patient not known to 
be dead), the highest proportion was 4%, and only in a 
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Africa
Algeria (Sétif) 38·8 (31·4–46·2) R 11·4 (0·7–40·9) R 30·6 (9·5–56·1) R 25·9 (11·4–43·7) R 18·2 (6·6–34·6) R 22·5 (10·6–37·7) R 22·6 (11·2–36·7) R 21·4 (8·7–38·9) R
America (Central and South)
Brazilian registries 58·4 (52·7–64·6) 33·1 (24·2–45·3) 32·7 (26·1–40·8) 49·3 (34·8–69·8) 38·4 (27·3–53·9) 47·3 (37·5–59·6) 43·5 (35·7–53·1) 49·3 (43·6–55·8)
Campinas 36·6 (27·8–48·3) 23·8 (13·1–36·8) R 21·4 (12·6–31·9) R .. .. .. .. 34·4 (25·2–47·0)
Goiânia 65·4 (58·3–73·2) 48·1 (36·7–63·1) 44·8 (35·2–56·9) 49·3 (34·8–69·8) 38·4 (27·3–53·9) 47·3 (37·5–59·6) 43·5 (35·7–53·1) 55·7 (49·0–63·3)




83·7 (83·5–83·9) 59·5 (59·1–59·9) 59·9 (59·5–60·3) 56·4 (55·8–56·9) 59·7 (59·1–60·3) 58·6 (58·3–58·9) 60·0 (59·7–60·3) 91·1 (90·9–91·3)
Canadian registries 82·5 (81·9–83·0) 56·1 (55·1–57·2) 58·7 (57·7–59·7) 53·1 (51·5–54·6) 58·7 (57·0–60·4) 55·3 (54·4–56·2) 58·9 (58·0–59·8) 85·1 (84·4–85·7)
   British Columbia 85·4 (84·2–86·5) 57·0 (54·5–59·6) 59·2 (56·8–61·7) 64·6 (59·9–69·7) 62·8 (57·5–68·6) 58·7 (56·4–61·0) 59·9 (57·7–62·2) 89·3 (88·1–90·5)
   Manitoba 82·9 (80·9–85·0) 57·4 (53·4–61·6) 59·8 (56·1–63·8) 54·6 (49·6–60·1) 58·1 (52·3–64·6) 56·4 (53·3–59·7) 59·5 (56·4–62·8) 87·5 (85·5–89·6)
   Nova Scotia 79·3 (77·0–81·8) 54·3 (50·0–58·9) 58·2 (54·3–62·4) .. .. .. .. 84·7 (81·8–87·6)
   Ontario 81·6 (80·9–82·3) 56·0 (54·8–57·3) 58·5 (57·3–59·7) 51·1 (49·3–52·9) 57·8 (55·8–59·8) 54·5 (53·5–55·6) 58·6 (57·5–59·6) 83·4 (82·5–84·3)
   Saskatchewan 82·8 (80·8–84·8) 55·4 (51·3–59·7) 58·0 (53·9–62·4) 54·8 (49·6–60·6) 61·1 (55·1–67·7) 55·2 (52·0–58·6) 59·1 (55·6–62·7) 77·5 (74·4–80·8)
US registries 83·9 (83·7–84·1) 60·1 (59·6–60·5) 60·1 (59·7–60·5) 56·9 (56·3–57·5) 59·8 (59·2–60·4) 59·1 (58·8–59·5) 60·2 (59·8–60·5) 91·9 (91·7–92·1)
   Atlanta,† GA 85·7 (84·0–87·4) 63·9 (60·2–67·7) 60·7 (57·8–63·7) 56·5 (50·9–62·7) 64·3 (59·4–69·7) 62·3 (59·3–65·6) 62·0 (59·4–64·7) 93·4 (91·8–94·9)
   California 84·6 (84·3–85·0) 60·4 (59·5–61·2) 59·5 (58·7–60·3) 57·2 (56·0–58·5) 60·1 (58·8–61·4) 59·4 (58·7–60·1) 59·9 (59·2–60·5) 90·4 (90·0–90·8)
      Los Angeles, CA 83·4 (82·6–84·2) 61·2 (59·6–62·9) 58·4 (56·9–60·0) 55·7 (53·3–58·1) 58·5 (56·1–61·0) 59·5 (58·1–60·8) 58·5 (57·2–59·8) 90·7 (89·9–91·5)
      San Francisco, CA 86·2 (85·2–87·2) 59·2 (57·1–61·4) 59·9 (57·9–62·0) 56·5 (53·4–59·8) 60·3 (57·1–63·7) 58·4 (56·6–60·2) 60·2 (58·4–62·0) 89·5 (88·4–90·6)
   Colorado 87·0 (85·8–88·2) 61·6 (59·0–64·4) 62·0 (59·5–64·6) 55·6 (51·7–59·8) 59·8 (55·9–64·0) 59·7 (57·5–62·0) 61·7 (59·6–63·8) 92·8 (91·6–93·9)
   Connecticut 85·7 (84·7–86·7) 62·3 (60·1–64·7) 63·4 (61·3–65·6) 61·3 (58·1–64·6) 62·4 (59·1–65·8) 62·0 (60·2–63·9) 63·4 (61·6–65·2) 91·7 (90·5–93·0)
   Florida 84·0 (83·5–84·5) 60·2 (59·2–61·3) 61·0 (60·0–62·0) 57·1 (55·5–58·7) 61·0 (59·4–62·6) 59·4 (58·5–60·2) 61·2 (60·3–62·1) 89·0 (88·4–89·5)
   Hawaii 89·3 (87·3–91·4) 67·9 (64·2–71·8) 66·5 (62·6–70·6) 59·3 (54·2–64·8) 61·0 (54·7–68·0) 65·0 (61·9–68·1) 65·5 (62·2–69·0) 90·9 (88·7–93·2)
   Idaho 86·3 (84·2–88·5) 61·4 (56·9–66·3) 63·4 (59·1–68·0) 66·9 (60·8–73·6) 60·0 (53·3–67·6) 63·6 (59·9–67·6) 62·8 (59·2–66·7) 91·7 (89·8–93·7)
   Iowa 86·6 (85·5–87·7) 60·8 (58·4–63·3) 64·8 (62·7–67·0) 59·0 (55·6–62·6) 63·8 (60·2–67·6) 60·3 (58·3–62·3) 64·7 (62·9–66·6) 92·6 (91·4–93·8)
   Louisiana 81·0 (79·9–82·2) 59·8 (57·5–62·1) 58·8 (56·8–60·7) 57·3 (53·9–60·9) 58·7 (55·5–62·1) 59·1 (57·3–61·1) 58·9 (57·2–60·6) 88·4 (87·2–89·6)
   Michigan‡ 82·3 (81·7–83·0) 58·7 (57·4–60·1) 59·3 (58·0–60·5) 55·2 (53·2–57·2) 59·2 (57·2–61·3) 57·8 (56·7–58·9) 59·4 (58·4–60·5) 100·0 (99·8–100)
      Detroit, MI 83·0 (82·0–84·1) 60·5 (58·3–62·8) 58·0 (56·0–60·1) 55·8 (52·6–59·1) 57·5 (54·2–60·9) 59·1 (57·3–61·0) 57·9 (56·2–59·6) 93·4 (92·4–94·4)
   Nebraska 85·4 (84·0–86·9) 60·4 (57·3–63·7) 64·2 (61·4–67·2) 58·3 (54·0–63·0) 60·6 (56·0–65·7) 59·8 (57·3–62·5) 63·6 (61·1–66·1) 92·8 (91·3–94·4)
   New Jersey 83·3 (82·6–84·0) 61·3 (59·9–62·7) 61·1 (59·8–62·5) 56·1 (54·0–58·2) 58·4 (56·3–60·5) 59·6 (58·4–60·8) 60·5 (59·4–61·6) 90·8 (90·1–91·6)
   New Mexico 84·6 (82·7–86·4) 62·0 (58·1–66·2) 61·6 (57·8–65·7) 52·6 (47·2–58·7) 59·1 (53·0–65·8) 59·0 (55·7–62·4) 61·0 (57·8–64·4) 92·4 (90·7–94·1)
   New York State 81·0 (80·5–81·5) 56·6 (55·6–57·7) 56·4 (55·5–57·4) 54·9 (53·4–56·4) 56·7 (55·2–58·2) 56·1 (55·3–57·0) 56·6 (55·8–57·4) 85·6 (85·0–86·2)
      New York City 77·4 (76·6–78·2) 54·2 (52·6–55·9) 53·6 (52·1–55·1) 50·6 (48·2–53·2) 52·4 (50·0–54·9) 53·2 (51·8–54·5) 53·3 (52·1–54·6) 81·6 (80·5–82·7)
   Rhode Island 84·6 (82·8–86·4) 64·7 (60·9–68·7) 63·5 (60·0–67·2) 60·1 (54·5–66·3) 59·9 (54·5–65·8) 63·3 (60·2–66·7) 62·8 (59·8–65·8) 90·8 (88·4–93·2)
   Seattle,† WA 88·6 (87·5–89·7) 63·7 (61·3–66·2) 64·1 (61·9–66·5) 60·7 (57·2–64·4) 65·4 (61·9–69·2) 63·0 (60·9–65·1) 64·8 (62·9–66·8) 95·0 (94·0–96·0)
   Utah 85·8 (84·0–87·7) 60·8 (56·8–65·1) 58·6 (54·5–63·0) 59·9 (54·2–66·2) 61·3 (55·0–68·2) 61·1 (57·8–64·6) 59·6 (56·2–63·3) 93·7 (92·2–95·2)
   Wyoming 84·3 (80·9–87·8) 59·5 (52·5–67·4) 58·5 (52·2–65·6) 46·5 (37·3–57·9) 52·3 (42·7–64·0) 56·0 (50·1–62·5) 57·8 (52·4–63·7) 92·2 (89·3–95·3)
Asia
Japanese registries 81·6 (79·7–83·5) 63·0 (61·3–64·8) 57·1 (55·5–58·8) 58·2 (55·9–60·5) 57·6 (55·2–60·1) 61·1 (59·7–62·5) 57·3 (55·9–58·6) 50·4 (46·3–54·9)
Fukui 83·1 (78·3–88·2) 68·5 (64·2–73·0) 62·8 (58·8–67·0) 59·6 (54·1–65·7) 61·6 (56·0–67·8) 65·3 (61·8–68·9) 62·4 (59·1–65·9) 54·1 (46·6–61·6) R
Osaka 79·4 (77·1–81·9) 59·6 (57·3–62·0) 52·5 (50·4–54·7) 54·4 (51·3–57·7) 55·2 (51·9–58·7) 57·6 (55·7–59·5) 53·3 (51·5–55·2) 51·1 (46·1–56·6)
Yamagata 87·3 (83·4–91·4) 67·5 (64·3–70·8) 63·7 (60·7–66·8) 63·7 (59·8–67·9) 61·8 (57·6–66·3) 66·0 (63·5–68·5) 63·0 (60·5–65·5) 49·4 (43·2–55·6) R
Europe
European registries 73·1 (72·9–73·4) 46·8 (46·3–47·2) 48·4 (48·0–48·8) 43·2 (42·7–43·7) 47·4 (46·9–48·0) 45·3 (45·0–45·6) 48·1 (47·7–48·4) 57·1 (56·7–57·6)
Austria (Tirol) 74·9 (71·9–78·1) 57·0 (51·5–63·0) 59·3 (54·3–64·7) 45·8 (39·1–53·8) 45·2 (37·6–52·8) R 52·7 (48·2–57·6) 55·1 (50·8–59·7) 86·1 (82·9–89·4)
Czech Republic 
(West Bohemia)
62·9 (58·9–67·1) 37·7 (33·0–43·0) 37·6 (33·3–42·5) 29·3 (25·2–34·1) 39·1 (33·8–45·2) 33·8 (30·5–37·6) 38·3 (34·9–42·0) 50·7 (44·4–58·0)
Denmark 73·6 (72·5–74·7) 44·7 (42·7–46·7) 48·6 (46·8–50·4) 43·4 (41·2–45·6) 45·9 (43·6–48·3) 44·2 (42·7–45·7) 47·7 (46·3–49·2) 38·4 (36·3–40·6)
Estonia 61·3 (57·9–64·8) 38·5 (33·7–44·1) 39·1 (35·3–43·2) 33·6 (28·4–39·7) 30·2 (26·0–35·1) 36·4 (32·8–40·4) 35·5 (32·6–38·6) 56·5 (52·3–60·9)
(Continues on next page)
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(Continued from previous page)
Finland 80·2 (79·0–81·4) 54·6 (51·6–57·8) 54·7 (52·5–57·1) 49·8 (46·8–53·0) 52·6 (49·7–55·6) 52·5 (50·4–54·7) 54·0 (52·2–55·8) 62·9 (60·6–65·2)
French registries 79·8 (78·2–81·4) 57·4 (54·4–60·7) 60·1 (57·2–63·2) 52·8 (49·3–56·7) 63·9 (60·1–67·8) 55·6 (53·3–58·1) 61·5 (59·2–64·0) 73·7 (70·5–77·1)
   Bas-Rhin 82·2 (79·7–84·7) 57·8 (53·5–62·5) 62·7 (58·8–66·9) 57·9 (52·6–63·7) 61·7 (56·0–67·9) 57·8 (54·4–61·4) 63·0 (59·6–66·6) 73·8 (69·4–78·4)
   Calvados 75·6 (72·5–78·8) 62·0 (56·0–68·5) 61·3 (56·0–67·1) 52·2 (45·6–59·8) 67·9 (62·0–74·5) 57·6 (53·1–62·5) 64·2 (60·1–68·5) 73·1 (68·4–78·2)
   Côte d’Or 78·1 (74·1–82·3) 50·6 (44·6–57·5) 52·6 (46·7–59·4) 45·3 (38·8–53·0) 61·3 (53·3–70·5) 48·7 (44·1–53·7) 55·3 (50·5–60·6) ··
   Isère 81·9 (78·6–85·2) .. .. .. .. .. .. ··
Germany
(Saarland)
75·5 (73·3–77·8) 52·0 (48·2–56·0) 56·2 (52·9–59·7) 47·8 (43·0–53·1) 52·5 (48·1–57·3) 50·1 (47·2–53·2) 55·0 (52·3–57·9) 76·4 (72·7–80·4)
Iceland 79·0 (73·5–85·0) 48·1 (39·0–59·3) 54·9 (45·2–66·6) 52·1 (31·9–71·4) R 48·4 (31·7–64·6) R 49·5 (41·0–59·9) 54·0 (45·9–63·6) 69·7 (62·2–78·1)
Ireland 69·6 (66·1–73·3) 49·1 (44·0–54·8) 48·5 (43·7–53·8) 41·1 (35·0–48·2) 52·5 (44·6–60·3) R 46·0 (42·0–50·4) 50·0 (45·9–54·5) 62·8 (58·0–68·0)
Italian registries 79·5 (78·8–80·3) 52·4 (51·1–53·8) 53·8 (52·6–55·0) 47·4 (45·7–49·2) 50·4 (48·6–52·3) 50·7 (49·7–51·8) 52·7 (51·7–53·8) 65·4 (63·7–67·2)
   Ferrara 78·8 (75·6–82·2) 48·5 (43·2–54·5) 54·9 (49·8–60·5) 44·6 (37·1–53·6) 48·0 (40·5–57·0) 47·3 (42·8–52·2) 53·6 (49·2–58·4) 69·8 (63·2–76·0) R
   Genoa 80·6 (78·3–83·0) 49·9 (45·9–54·2) 51·2 (47·5–55·3) 40·5 (35·2–46·6) 45·4 (40·0–51·5) 46·8 (43·5–50·3) 49·5 (46·3–52·9) 66·2 (61·0–71·9)
   Latina  81·8 (76·4–87·5) 52·7 (45·3–61·3) 57·4 (49·9–65·9) 46·3 (36·3–56·2) R 45·1 (34·7–58·5) 51·2 (45·0–58·2) 53·3 (47·1–60·3) 61·0 (53·9–69·1)
   Macerata 77·5 (73·0–82·4) 48·9 (42·8–55·9) 57·9 (51·7–65·0) 42·0 (34·1–51·8) 52·1 (41·2–62·6) R 46·7 (41·6–52·3) 56·8 (51·4–62·7) 69·7 (63·1–76·0) R
   Modena 83·1 (80·4–85·8) 55·0 (50·5–59·9) 52·0 (47·7–56·5) 48·4 (42·5–55·1) 45·3 (39·0–52·5) 52·8 (49·2–56·7) 49·8 (46·2–53·7) 68·7 (61·7–76·6)
   Parma 81·2 (78·1–84·4) 50·7 (45·6–56·4) 53·7 (48·3–59·7) 47·4 (39·9–54·9) R 41·6 (34·7–49·7) 49·8 (45·6–54·5) 49·3 (44·9–54·2) 56·1 (48·0–65·6)
   Ragusa 68·9 (63·2–75·1) 39·5 (32·0–48·8) 44·0 (36·8–52·6) 50·3 (40·8–61·9) 37·8 (26·0–50·3) R 44·9 (38·7–52·1) 41·9 (35·9–48·9) 49·9 (41·0–58·9) R
   Romagna 87·4 (84·4–90·4) 51·4 (46·2–57·1) 58·7 (54·0–63·8) 51·0 (42·9–59·0) R 57·9 (50·8–65·9) 50·9 (46·6–55·5) 58·4 (54·4–62·7) 73·3 (67·9–79·2)
   Sassari 76·4 (71·3–81·9) 39·9 (31·2–51·0) 41·5 (32·0–51·0) R 44·5 (34·2–54·8) R 42·8 (31·5–58·0) 42·3 (35·8–50·1) 43·5 (36·5–51·8) 52·2 (42·8–61·5) R
   Turin 79·4 (77·1–81·7) 50·1 (46·1–54·5) 51·4 (47·8–55·4) 43·7 (39·0–49·0) 54·0 (48·8–59·6) 47·8 (44·7–51·2) 52·4 (49·3–55·6) 63·2 (58·1–68·8)
   Tuscany 80·8 (78·9–82·7) 55·6 (52·5–58·9) 54·4 (51·4–57·5) 50·8 (46·9–55·0) 48·7 (44·6–53·2) 53·8 (51·4–56·4) 52·5 (50·1–55·1) 66·4 (62·4–70·7) 
   Varese    77·6 (75·2–80·0) 55·3 (51·0–59·9) 55·1 (51·1–59·5) 52·4 (46·5–59·0) 53·4 (47·8–59·6) 54·5 (51·1–58·2) 54·5 (51·1–58·1) 72·2 (66·7–78·2)
   Veneto 77·6 (76·2–79·1) 53·7 (50·9–56·7) 54·6 (52·0–57·3) 48·4 (44·6–52·5) 55·7 (51·7–60·0) 52·0 (49·8–54·4) 55·0 (52·8–57·2) 61·8 (58·5–65·3)
Malta 73·5 (66·7–81·1) 38·0 (25·9–50·7) R 58·0 (46·5–72·4) 34·7 (20·8–49·9) R 52·5 (31·9–71·4) R 35·7 (27·0–47·1) 55·5 (46·1–66·8) 44·3 (32·3–56·9) R
Netherlands 
registries
77·6 (76·6–78·6) 52·7 (50·1–55·4) 55·4 (53·2–57·7) 55·0 (51·6–58·6) 54·5 (51·3–57·9) 53·6 (51·5–55·7) 55·1 (53·3–57·0) 69·5 (67·2–71·9)
  Amsterdam 78·0 (76·5–79·4) 52·1 (49·1–55·2) 54·1 (51·6–56·7) 51·5 (47·6–55·7) 56·4 (52·7–60·3) 51·9 (49·5–54·3) 54·8 (52·7–57·0) 68·1 (65·4–70·8)
  Netherlands 
  (North)
77·8 (76·2–79·4) .. .. .. ·· ·· ·· ··
  Netherlands 
  (South)
75·7 (72·9–78·5) 54·2 (49·2–59·8) 59·4 (54·9–64·2) 62·1 (56·6–68·1) 49·2 (43·1–56·1) 58·0 (54·2–62·2) 56·1 (52·5–60·0) 74·9 (70·3–79·8)
Norway 76·3 (75·1–77·6) 50·8 (48·7–53·0) 54·4 (52·5–56·3) 51·3 (48·9–53·9) 56·9 (54·3–59·6) 51·1 (49·5–52·8) 55·3 (53·8–56·9) 63·0 (60·9–65·1)
Polish registries 62·9 (60·6–65·3) 28·5 (25·3–32·1) 30·9 (28·0–34·2) 28·4 (24·7–32·7) 30·2 (26·7–34·1) 28·6 (26·1–31·3) 30·6 (28·3–33·0) 37·1 (33·0–41·6)
   Cracow 54·7 (50·6–59·1) 24·6 (18·8–32·1) 23·4 (17·9–30·7) 25·0 (18·9–33·3) 22·9 (16·8–31·1) 25·7 (21·5–30·8) 22·5 (18·3–27·6) 21·3 (15·2–29·9)
   Warsaw 66·1 (63·4–68·9) 29·7 (26·1–33·9) 33·6 (30·3–37·4) 29·2 (24·9–34·2) 32·6 (28·6–37·3) 29·6 (26·8–32·7) 33·0 (30·3–35·8) 41·4 (36·5–46·8)
Portugal (South) 72·2 (68·2–76·5) 48·6 (42·6–55·4) 44·8 (39·1–51·3) 42·3 (35·5–50·4) 44·5 (37·8–52·4) 46·5 (41·8–51·8) 44·7 (40·2–49·7) 47·7 (40·7–54·8) R
Slovakia 57·9 (55·9–59·9) 40·1 (37·7–42·7) 44·1 (41·7–46·7) 27·6 (25·5–29·8) 32·3 (29·9–34·8) 34·0 (32·3–35·8) 38·7 (37·0–40·5) 45·7 (42·7–49·0)
Slovenia 66·3 (63·8–68·9) 37·3 (33·5–41·5) 39·8 (36·3–43·6) 34·0 (30·5–38·0) 35·6 (32·1–39·5) 35·7 (33·1–38·5) 37·7 (35·3–40·4) 43·7 (39·4–48·4)
Spanish registries 77·7 (76·4–79·0) 54·2 (52·2–56·3) 56·3 (54·2–58·4) 50·0 (47·7–52·4) 51·8 (49·1–54·6) 52·5 (51·0–54·1) 54·7 (53·1–56·4) 60·5 (57·6–63·6)
   Basque Country 79·5 (77·6–81·5) 59·0 (55·8–62·3) 58·3 (55·0–61·8) 53·3 (49·6–57·3) 52·2 (47·8–56·9) 56·5 (54·1–59·0) 56·2 (53·5–58·9) 63·0 (58·8–67·4)
   Granada 71·8 (67·0–77·0) 50·6 (44·3–57·8) 50·9 (44·5–58·2) 45·7 (38·1–54·8) 51·1 (43·0–60·8) 48·2 (43·3–53·7) 51·1 (46·0–56·8) ..
   Mallorca 80·1 (77·2–83·2) 51·4 (46·4–57·1) 57·4 (52·2–63·0) 48·9 (42·5–56·2) 51·7 (44·5–59·9) 50·9 (46·9–55·3) 56·1 (51·8–60·7) 68·2 (60·7–76·6)
   Murcia 72·8 (69·1–76·8) 49·7 (44·4–55·7) 54·8 (50·2–59·9) 49·2 (43·4–55·8) 47·8 (42·0–54·4) 49·7 (45·5–54·3) 52·3 (48·7–56·3) 52·0 (45·4–59·4)
   Navarra 78·3 (74·9–81·8) 50·6 (45·1–56·8) 53·3 (46·8–60·8) 42·7 (36·4–50·1) 58·1 (49·1–66·5) R 47·7 (43·4–52·4) 55·6 (50·4–61·3) 54·6 (47·2–63·0)
   Tarragona 76·4 (73·0–80·0) 49·2 (43·9–55·1) 52·8 (47·8–58·3) 50·1 (43·2–58·0) 49·8 (40·9–58·4) R 49·6 (45·4–54·3) 51·7 (47·4–56·4) 54·6 (46·3–64·3)
   Sweden 82·0 (81·2–82·7) 52·5 (50·9–54·2) 54·8 (53·3–56·3) 53·0 (51·2–55·0) 58·2 (56·3–60·2) 52·8 (51·6–54·1) 56·2 (55·0–57·4) 66·0 (64·7–67·3)
Swiss registries 76·0 (74·3–77·7) .. .. .. .. ·· ·· ··
   Basel 78·2 (75·1–81·4) .. .. .. .. ·· ·· ··
   Geneva 79·1 (76·0–82·4) .. .. .. .. ·· ·· ··
(Continues on next page)
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very few registries was it greater than 1% (available on-
line34). Such patients are described as censored from the 
analysis.
Statistical analysis
We estimated relative survival up to 5 years after diagnosis 
from the individual tumour data, using the Hakulinen 
approach44 embedded in the US National Cancer Institute’s 
publicly accessible SEER*Stat software.45 SEER*Stat is 
the standard tool used for cancer-survival estimation by the 
SEER Program cancer registries, and we used it to ensure 
that survival estimates for US registries would be seen as 
comparable with those already published by the SEER 
Program. Survival estimates were also derived by race for 
the USA (black and white).
Relative survival is the ratio of the survival noted in the 
patients with cancer and the survival that would have been 
expected had they been subject only to the mortality rates 
of the general population (background mortality). It is a 
measure of the excess mortality in patients with cancer 
over and above the background mortality, and can be inter-
preted as survival from the cancer after correction for other 
causes of death. This approach is crucial for inter national 
comparisons of cancer survival, because the back ground 
risks of death from all causes in adults often diﬀ er very 
widely. Background mortality was taken from life tables 
developed specially for the CONCORD study, speciﬁ c for 
sex, calendar year, region, and race.46
The probability of survival in successive years after 
diagnosis was estimated in survivors to the start of each 
year. We report the cumulative relative survival at 5 years. 
Survival was not estimated if fewer than ﬁ ve patients with 
a given cancer were available for analysis in any category 
deﬁ ned by age, sex, and race. Relative survival was adjusted 
Breast Colon Rectum Colorectum Prostate 
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
RS (%) (95% CI)
(Continued from previous page)
   Graubunden-
   Glarus
71·7 (66·8–77·0) .. .. .. ·· .. ·· ··
   St Gallen-
   Appenzell
71·7 (68·1–75·5) .. .. .. .. ·· ·· ··
   Valais 75·3 (70·4–80·6) .. .. .. ·· .· ·· ··
UK 69·7 (69·4–70·1) 43·5 (42·9–44·1) 44·4 (43·8–45·0) 40·6 (39·9–41·3) 45·3 (44·5–46·1) 42·3 (41·8–42·8) 44·7 (44·3–45·2) 51·1 (50·4–51·8)
   England (national) 69·8 (69·5–70·2) 43·4 (42·8–44·1) 44·3 (43·7–45·0) 40·4 (39·6–41·2) 45·4 (44·6–46·3) 42·2 (41·7–42·7) 44·7 (44·2–45·3) 50·9 (50·1–51·7)
      East Anglia 70·8 (69·2–72·4) 43·6 (40·8–46·7) 42·9 (40·2–45·8) 46·0 (42·4–49·8) 49·8 (46·1–53·9) 44·6 (42·4–47·0) 45·2 (43·0–47·6) 51·9 (48·4–55·7)
      Mersey 69·4 (67·8–71·1) 43·8 (41·0–46·9) 43·6 (41·0–46·4) 41·2 (38·1–44·5) 44·5 (41·0–48·2) 43·0 (40·9–45·1 ) 44·0 (41·8–46·2) 52·6 (49·3–56·1)
      Oxford 71·1 (69·6–72·6) 44·8 (42·1–47·8) 45·0 (42·4–47·8) 43·1 (39·8–46·6) 45·6 (41·8–49·7) 44·3 (42·1–46·6) 45·3 (43·2–47·6) 50·4 (47·4–53·6)
      South Thames 73·9 (73·0–74·9) 45·5 (43·6–47·6) 48·3 (46·5–50·2) 45·3 (43·0–47·8) 51·1 (48·6–53·6) 45·5 (44·0–47·1) 49·3 (47·9–50·8) 56·1 (54·0–58·2)
      South West 73·4 (72·5–74·2) 51·5 (49·8–53·1) 51·6 (50·1–53·2) 48·6 (46·7–50·6) 52·0 (49·8–54·2) 50·3 (49·0–51·5) 51·8 (50·5–53·1) 55·8 (53·9–57·9)
      Trent 68·2 (67·2–69·3) 40·3 (38·3–42·5) 42·2 (40·2–44·2) 39·3 (37·1–41·6) 43·8 (41·3–46·5) 39·8 (38·3–41·4) 42·9 (41·3–44·5) 47·0 (44·8–49·4)
      West Midlands 75·4 (74·2–76·5) 48·0 (46·2–49·9) 48·4 (46·6–50·2) 44·4 (42·2–46·7) 46·9 (44·3–49·6) 46·6 (45·2–48·1) 48·0 (46·5–49·5) 55·4 (53·2–57·7)
      Yorkshire 71·4 (70·1–72·8) 45·5 (43·1–48·1) 45·4 (43·1–47·8) 43·8 (41·1–46·7) 49·8 (46·8–53·0) 44·7 (42·9–46·6) 47·0 (45·1–48·9) 53·3 (50·5–56·4)
  Northern Ireland 72·0 (68·9–75·3) 47·3 (42·1–53·0) 49·0 (44·3–54·3) 48·2 (41·6–55·8) 43·8 (37·0–51·9) 47·8 (43·7–52·3) 47·8 (43·8–52·2) 54·0 (48·7–59·9)
  Scotland 70·6 (69·5–71·8) 45·9 (44·0–47·9) 47·8 (46·1–49·6) 42·3 (39·9–44·9) 46·9 (44·4–49·6) 44·6 (43·1–46·2) 47·7 (46·2–49·2) 54·2 (52·0–56·5)
   Wales 67·1 (65·8–68·4) 39·9 (37·5–42·6) 38·0 (35·7–40·4) 39·5 (36·8–42·3) 41·9 (38·8–45·2) 39·8 (38·0–41·8) 39·3 (37·5–41·3) 47·9 (44·9–51·1)
Oceania
Australia (national) 80·7 (80·1–81·3) 57·8 (56·8–58·8) 57·7 (56·7–58·6) 54·8 (53·6–56·1) 59·2 (57·8–60·6) 56·7 (55·9–57·5) 58·2 (57·4–58·9) 77·4 (76·6–78·2)
   Australian Capital 
   Territory
80·4 (74·3–87·0) 62·0 (53·8–71·5) 59·1 (51·2–68·2) 57·2 (45·5–68·1) R 61·3 (49·8–75·5) 56·5 (49·1–65·1) 59·8 (53·0–67·5) 78·7 (72·5–85·5)
   New South Wales 80·4 (79·4–81·5) 60·8 (59·1–62·6) 58·2 (56·6–59·9) 56·9 (54·7–59·1) 59·6 (57·3–61·9) 59·3 (57·9–60·7) 58·7 (57·4–60·0) 78·3 (77·0–79·6)
   Northern Territory 71·9 (58·7–88·0) 53·5 (36·3–69·4) R 51·7 (34·2–67·5) R 46·3 (28·9–63·4) R 66·5 (39·6–86·0) R 52·1 (38·6–70·5) 53·2 (39·9–70·9) 63·7 (49·0–77·0) R
   Queensland 80·5 (79·0–82·0) 59·8 (57·5–62·3) 60·6 (58·6–62·8) 53·7 (50·7–56·9) 61·2 (57·7–64·8) 57·7 (55·8–59·6) 60·7 (58·9–62·5) 75·7 (73·9–77·6)
   Southern Australia 80·0 (78·0–82·0) 56·3 (53·0–59·8) 58·6 (55·5–61·8) 55·2 (51·3–59·4) 59·2 (55·1–63·6) 55·8 (53·3–58·4) 58·6 (56·1–61·2) 77·1 (74·3–80·1)
   Tasmania 77·1 (73·4–81·1) 52·4 (46·8–58·6) 50·0 (44·9–55·6) 44·9 (37·5–53·6) 55·0 (46·8–64·6) 50·2 (45·7–55·1) 51·8 (47·4–56·6) 70·2 (65·8–74·8)
   Victoria 81·5 (80·4–82·7) 54·7 (52·7–56·7) 56·1 (54·3–57·9) 54·9 (52·5–57·4) 59·0 (56·5–61·6) 54·8 (53·3–56·4) 57·2 (55·7–58·6) 76·8 (75·2–78·4)
   Western Australia 81·4 (79·3–83·5) 53·2 (49·7–56·9) 54·5 (51·4–57·8) 50·9 (46·8–55·3) 54·8 (50·3–59·7) 52·5 (49·8–55·3) 54·8 (52·1–57·5) 80·0 (77·7–82·3)
RS=relative survival. R=raw (not age-standardised) survival estimate: too few cases in one or more age groups. *International Cancer Survival Standard (see text). †No state-wide data available for this city. 
‡Survival truncated if greater than 1·0 (100%). 95% CIs were calculated by use of a logarithmic transformation (see text).
Table 2: 5-year relative survival (%), age-standardised to ICSS weights* with 95% CIs for adults (aged 15–99 years) diagnosed with cancer of the breast (women), colon, rectum, or 
prostate during 1990–94 and followed up to Dec 31, 1999: continent, country, and region
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for heterogeneity in the withdrawal of patients from follow-
up and consequent changes in the age-sex-race distribution 
of patients with cancer in successive calendar years, by use 
of the exact method.44
Expected survival was derived from complete life tables 
that contained the probabilities of death or the central 
death rates for the general population of the registry’s 
territory, by single year of age, sex and (where possible) 
race, and single calendar year between 1990 and 1999. 
Many registries provided complete life tables. For some 
registries, complete life tables were constructed from 
raw data obtained from published sources on the 
numbers of deaths by age, sex, and race in the relevant 
year(s) or period, and the corresponding populations. 
For the remaining registries, abridged (5-year or 10-year 
age groups) life tables from published sources were 
smoothed to produce complete life tables. In some 
registries, life tables were interpolated, as required, to 
provide life tables by single calendar year throughout the 
decade 1990–99. Details are provided in an accompanying 
paper.46 
Cancer survival is known to vary with race,47–55 and we 
assessed racial diﬀ erences in survival where possible. 
Individual tumour records were coded by race only in the 
data from the USA (black, white, other). Race-speciﬁ c 
estimates of relative survival were produced with separate 
life tables for each race, constructed from the raw data on 
populations and the number of deaths.46
In the USA, race-speciﬁ c mortality in the general 
population also varies between states.36 We developed 
separate sets of complete life tables for each state and 
metropolitan area and for each sex. This approach was 
designed to enable the closest possible adjustment of 
relative survival estimates in the USA for geographic 
variation in background mortality in both blacks and 
whites, by age, sex, and calendar period. Race-speciﬁ c life 
tables for both blacks and whites were developed for 11 of 
the 16 states and all six metropolitan areas. Where race-
speciﬁ c life tables were available, they were used in the 
estimation of relative survival for patients of that race. For 
other patients, the all-races life table for that population 
was used. For ﬁ ve less populous states (Hawaii, Idaho, 
New Mexico, Utah, and Wyoming: 6% of the 109 million 
population covered by participating registries; webtable), 
only the life tables for whites were suﬃ  ciently robust, and 
relative survival estimates for blacks are not separately 
presented.
Relative survival measures the extent to which patients 
with cancer have a higher death rate than the general 
population of the country or region in which they live.56 
Occasionally, despite use of the most appropriate life table, 
this excess death rate can be negative in a given time 
interval since diagnosis, implying that the death rate of 
cancer survivors during that interval is actually lower than 
that of the general population. This situation can arise 
from random variation in the death rate when the number 
of deaths in the interval is small,57 either because the 
interval is very short, or because survival is poor and most 
patients have already died before the start of the interval, or 
because survival is high and there are very few deaths. In 
such situations, we present by default the estimate derived 
by use of the SEER*Stat option to constrain the excess 
mortality rate to zero, which imposes a plateau in the 
relative survival curve. The unconstrained estimate was 
also obtained for comparison.
Even though relative survival is already adjusted for age-
speciﬁ c diﬀ erences in background mortality, robust 
international comparison of relative survival requires age-
standard isation,23 because the age distribution of patients 
with cancer varies between countries, and because relative 
survival also varies widely by age, at least in Europe.27 
Conventional age-speciﬁ c weights used to standardise 
incidence or mortality rates (eg, the national population or 
the hypothetical world standard population58) are unsuitable 
because patients with cancer have a very diﬀ erent age 
proﬁ le from that of the general population.
A cancer-survival comparison of such wide scope has not 
been done before and the choice of weights for age-
standardisation was not straightforward. International 
stan dard cancer-patient populations have been proposed, 
with diﬀ erent sets of weights in 5-year or 10-year age bands 
for each of 20 common cancers, derived from their world-
wide distribution.59 The weights used for the EUROCARE-3 
study were derived from the age distribution of all patients 
included in that study for each cancer, and were thus 
cancer-speciﬁ c.43 The disadvantage of these standards is 
either that a unique set of weights is required for each cancer 
(cancer-speciﬁ c), or else that the standards are arbitrary 
(study-speciﬁ c), vitiating comparison between studies.
We chose the recently developed International Cancer 
Survival Standard (ICSS) weights.60 These comprise just 
three sets of age weights, derived from discriminant 
analysis to ﬁ nd the smallest number of sets of standard 
age weights that enable adequate standardisation of 
survival. Each standard is applicable to a range of diﬀ erent 
cancers, and provides age-standardised survival estimates 
that are not too diﬀ erent from the unstandardised 
estimates. The ﬁ rst ICSS standard applies to cancers for 
which incidence rises rapidly with age, and we used this in 
all analyses. For cancers of the breast, colon, and rectum, 
we used ﬁ ve age groups: 15–44, 45–54, 55–64, 65–74, and 
75–99 years. For prostate cancer, which occurs mainly in 
older men, we used four age groups: 15–54, 55–64, 65–74, 
and 75–99 years. Where data were too sparse for 
standardisation, the raw (unstandardised) survival estimate 
is presented, ﬂ agged with “R”.
The same age weights were used for men and women, 
and for each race, enabling direct comparison of age-
standardised relative survival between patient groups 
deﬁ ned by sex and race. Because identical weights were 
used for breast, colon, and rectal cancer, the age-
standardised estimates of survival for these cancers can 
also be directly compared. This would not be possible if 
cancer-speciﬁ c weights were used.
See Online for webtable
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Africa
America, Central and South

















































































































































5-year relative survival (%) 5-year relative survival (%)
Figure 1: 5-year relative 
survival (%), age-
standardised to the ICSS 
weights* with 95% CIs for 
adults (aged 15–99 years) 
diagnosed with cancer of the 
breast (women), colorectum, 
or prostate during 1990–94 
and followed up to Dec 31, 
1999: country
Vertical bar on the right of 
each graphic shows the 
contribution (%) of each
continent to the total number 
of cases analysed 
(contributions under 1% are 
not labelled). Red vertical line 
represents mean survival for 
the 22 European countries 
that participated in 
EUROCARE-3, age-
standardised to ICSS weights. 
Switzerland only provided 
data for breast cancer. *Age-
standardised to ICSS weights, 
except for Sétif, Algeria (all 
cancers), Malta (prostate), and 
Portugal (prostate), which 
were unstandardised values 
(see text). †Problems with 
data quality might have led
to over-estimation (see text). 
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Figure 2: 5-year relative 
survival (%), using state-
speciﬁ c and race-speciﬁ c life 
tables and age-standardised 
to the ICSS weights* for 
adults (aged 15–99 years) 
diagnosed with cancer of the 
breast (women), colon, 
rectum, colon and rectum 
combined, or prostate 
during 1990–94 and 
followed up to Dec 31, 1999: 
16 US States and six 
metropolitan areas 
Vertical lines represent mean 
survival for SEER (red) and 
NPCR (green) registries, age-
standardised to ICSS weights 
(see text). *Age-standardised 
to ICSS weights (see text). 
†Problems with data quality 
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For countries represented by more than one regional 
cancer registry, we provide a survival estimate derived from 
the pooled data for all contributing registries, age-
standardised in the same way. This is an overall estimate of 
survival in the combined territories providing data from 
that country, not a weighted mean of the various regional 
estimates. The combined estimate should not be 
considered as necessarily representative of survival in the 
country as a whole, except where the regional registries 
cover the entire country.
Breast Colon Rectum Colorectum Prostate
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
RS (%) (95% CI)
Atlanta, GA (all races), S 85·7 (84·0–87·4) 64·1 (60·5–68·0) 60·9 (58·0–63·9) 56·6 (51·0–62·8) 64·5 (59·5–69·8) 62·5 (59·4–65·8) 62·2 (59·6–64·9) 94·0 (92·4–95·6)
Black 71·1 (67·1–75·4) 59·9 (52·3–68·5) 52·6 (47·2–58·6) 45·5 (35·3–58·6) 52·1 (42·5–63·7) 56·8 (50·3–64·2) 52·9 (48·1–58·2) 86·5 (83·3–89·8)
White 89·6 (87·8–91·5) 65·4 (61·3–69·8) 63·9 (60·5–67·6) 59·4 (52·9–66·7) 67·9 (62·3–74·1) 64·1 (60·6–67·8) 65·4 (62·4–68·4) 96·1 (94·4–97·9)
California (all races), N 84·9 (84·5–85·3) 60·8 (59·9–61·6) 59·8 (59·0–60·6) 57·5 (56·3–58·8) 60·3 (59·0–61·6) 59·8 (59·1–60·5) 60·1 (59·4–60·8) 91·1 (90·6–91·5)
Black 73·4 (71·4–75·6) 54·8 (51·4–58·4) 51·1 (48·3–54·2) 50·3 (44·9–56·4) 50·9 (45·9–56·4) 53·6 (50·7–56·7) 51·2 (48·7–53·8) 84·5 (82·9–86·1)
White 85·3 (84·9–85·7) 60·7 (59·8–61·6) 60·1 (59·2–61·0) 57·4 (56·1–58·7) 60·4 (59·0–61·8) 59·7 (58·9–60·4) 60·3 (59·6–61·0) 90·8 (90·3–91·2)
Los Angeles, CA (all 
races), N
83·8 (83·0–84·6) 61·9 (60·2–63·6) 58·8 (57·3–60·3) 56·2 (53·8–58·6) 58·8 (56·4–61·3) 60·0 (58·7–61·4) 58·8 (57·6–60·2) 91·7 (90·9–92·6)
Black 72·5 (69·6–75·6) 58·9 (54·5–63·8) 52·1 (48·2–56·3) 49·8 (42·3–58·7) 50·1 (43·4–57·9) 57·0 (53·2–61·2) 51·7 (48·2–55·3) 84·8 (82·5–87·3)
White 84·7 (83·9–85·5) 61·5 (59·7–63·4) 59·4 (57·6–61·2) 55·4 (52·8–58·2) 58·5 (55·7–61·4) 59·6 (58·0–61·1) 59·2 (57·7–60·7) 92·3 (91·4–93·2)
San Francisco, CA (all 
races), S
86·6 (85·6–87·6) 59·8 (57·6–62·0) 60·3 (58·2–62·5) 57·0 (53·8–60·3) 60·6 (57·4–64·0) 58·9 (57·2–60·8) 60·5 (58·8–62·3) 90·5 (89·4–91·6)
Black 77·2 (73·2–81·4) 47·4 (41·0–54·7) 50·0 (44·4–56·4) 54·7 (43·7–68·5) 52·3 (41·5–66·0) 49·7 (44·2–56·0) 50·6 (45·6–56·2) 83·7 (80·4–87·1)
White 87·5 (86·5–88·6) 60·3 (57·9–62·9) 61·1 (58·7–63·6) 56·8 (53·2–60·5) 61·5 (57·9–65·4) 59·3 (57·3–61·4) 61·4 (59·4–63·5) 90·2 (88·9–91·4)
Colorado (all races), N 87·0 (85·8–88·2) 61·7 (59·1–64·5) 62·0 (59·6–64·6) 55·6 (51·7–59·9) 59·8 (55·9–64·0) 59·8 (57·6–62·1) 61·7 (59·6–63·9) 92·9 (91·8–94·1)
Black 81·6 (74·1–89·9) 45·0 (34·3–58·8) 48·0 (36·9–62·5) 76·8 (44·8–97·7) R 39·6 (16·2–64·9) R 49·7 (39·3–63·0) 46·7 (36·2–60·2) 80·7 (74·6–87·4)
White 87·0 (85·8–88·2) 62·1 (59·4–65·0) 62·3 (59·8–65·0) 54·9 (50·9–59·2) 60·6 (56·6–64·9) 59·8 (57·6–62·2) 62·1 (60·0–64·4) 92·8 (91·6–94·0)
Connecticut (all races), S 85·7 (84·7–86·8) 62·4 (60·2–64·7) 63·5 (61·4–65·7) 61·3 (58·1–64·6) 62·4 (59·1–65·9) 62·1 (60·3–64·0) 63·4 (61·6–65·2) 91·9 (90·7–93·2)
Black 75·2 (69·3–81·6) 51·1 (41·9–62·3) 52·7 (44·8–61·9) 63·5 (47·5–85·0) 73·3 (56·8–86·2) R 54·4 (46·0–64·3) 56·5 (49·4–64·6) 82·3 (77·6–87·2)
White 86·3 (85·3–87·3) 62·9 (60·6–65·3) 64·1 (61·9–66·4) 61·3 (58·1–64·7) 61·9 (58·5–65·5) 62·4 (60·5–64·3) 63·7 (61·9–65·6) 92·3 (91·0–93·6)
Florida (all races), N 84·0 (83·5–84·5) 60·2 (59·2–61·2) 61·0 (60·0–62·1) 57·0 (55·5–58·6) 61·0 (59·4–62·7) 59·4 (58·5–60·2) 61·2 (60·4–62·1) 89·2 (88·7–89·8)
Black 72·7 (70·1–75·3) 54·4 (50·0–59·1) 54·3 (50·9–57·9) 44·8 (37·7–53·1) 54·5 (48·4–61·3) 51·6 (47·8–55·6) 54·8 (51·9–58·0) 84·7 (82·7–86·7)
White 84·7 (84·2–85·2) 60·5 (59·4–61·6) 61·6 (60·5–62·7) 57·8 (56·2–59·5) 61·3 (59·6–63·1) 59·8 (59·0–60·8) 61·7 (60·8–62·6) 89·7 (89·1–90·3)
Hawaii (all races), S 90·2 (88·1–92·3) 68·4 (64·7–72·3) 67·2 (63·3–71·3) 59·6 (54·5–65·2) 61·5 (55·1–68·6) 65·4 (62·4–68·6) 66·2 (62·8–69·7) 91·8 (89·6–94·1)
White 90·2 (86·5–94·1) 67·9 (61·2–75·2) 61·6 (54·1–70·1) 54·0 (44·3–65·8) 66·0 (50·8–79·0) R 64·6 (58·6–71·1) 62·9 (56·2–70·3) 92·4 (89·0–96·0)
Idaho (all races), N 86·3 (84·2–88·5) 61·4 (56·9–66·3) 63·4 (59·1–68·0) 66·9 (60·8–73·6) 60·0 (53·3–67·6) 63·6 (59·9–67·6) 62·8 (59·1–66·7) 91·7 (89·8–93·7)
White 86·3 (84·2–88·5) 61·4 (56·8–66·4) 63·4 (59·1–68·1) 66·7 (60·5–73·4) 59·9 (53·1–67·5) 63·6 (59·8–67·5) 62·8 (59·1–66·8) 91·5 (89·5–93·5)
Iowa (all races), S 86·6 (85·5–87·7) 60·8 (58·4–63·3) 64·8 (62·7–67·0) 59·0 (55·6–62·6) 63·8 (60·2–67·6) 60·3 (58·3–62·3) 64·7 (62·9–66·6) 92·7 (91·5–93·9)
Black 60·1 (46·6–77·5) 66·8 (39·0–89·6) R 75·2 (51·7–94·1) R 56·5 (17·3–91·4) R 40·7 (12·5–71·8) R 66·9 (43·7–86·2) R 65·9 (46·5–82·8) R 85·8 (72·3–97·6) R
White 86·8 (85·7–87·8) 60·8 (58·4–63·3) 64·6 (62·5–66·8) 58·7 (55·3–62·4) 63·8 (60·2–67·7) 60·2 (58·2–62·2) 64·6 (62·7–66·5) 92·6 (91·4–93·8)
Louisiana (all races), N 81·0 (79·8–82·1) 59·9 (57·6–62·2) 58·8 (56·9–60·8) 57·2 (53·8–60·9) 58·7 (55·5–62·1) 59·2 (57·3–61·1) 58·9 (57·2–60·6) 88·6 (87·4–89·9)
Black 69·9 (67·2–72·7) 54·2 (49·6–59·3) 53·1 (49·6–56·9) 48·0 (40·8–56·4) 48·2 (41·9–55·4) 53·1 (49·2–57·2) 52·4 (49·2–55·8) 80·6 (78·1–83·2)
White 84·0 (82·8–85·3) 61·6 (59·1–64·3) 60·6 (58·4–63·0) 58·4 (54·6–62·4) 61·4 (57·8–65·3) 60·7 (58·6–62·9) 61·1 (59·2–63·1) 91·0 (89·6–92·4)
Michigan (all races)‡, N 82·3 (81·6–82·9) 58·8 (57·5–60·2) 59·3 (58·1–60·6) 55·2 (53·2–57·2) 59·2 (57·2–61·3) 57·8 (56·7–59·0) 59·5 (58·4–60·6) 100 (99·8–100) 
Black‡ 69·6 (67·2–72·1) 47·9 (44·2–51·9) 51·8 (48·5–55·4) 45·1 (39·1–51·9) 45·1 (39·3–51·8) 47·1 (43·9–50·6) 50·5 (47·6–53·6) 100 (99·3–100) 
White‡ 83·3 (82·6–84·0) 59·7 (58·3–61·2) 60·2 (58·9–61·6) 55·9 (53·8–58·1) 60·2 (58·1–62·4) 58·7 (57·5–59·9) 60·4 (59·3–61·6) 100 (99·8–100)
Detroit, MI (all races), S 83·0 (81·9–84·0) 60·6 (58·4–62·9) 58·2 (56·2–60·3) 55·7 (52·5–59·0) 57·4 (54·2–60·9) 59·2 (57·3–61·0) 58·0 (56·3–59·8) 93·8 (92·8–94·8)
Black 71·7 (68·9–74·6) 50·6 (45·9–55·8) 51·3 (47·6–55·4) 48·4 (40·9–57·2) 44·5 (37·4–53·0) 49·8 (45·7–54·2) 50·5 (47·1–54·3) 88·7 (86·4–91·1)
White 85·4 (84·3–86·5) 62·7 (60·2–65·3) 60·7 (58·3–63·2) 57·4 (53·9–61·0) 59·6 (55·9–63·4) 61·1 (59·1–63·2) 60·3 (58·3–62·4) 95·3 (94·2–96·4)
Nebraska (all races), N 85·4 (84·0–86·8) 60·4 (57·3–63·7) 64·3 (61·4–67·2) 58·3 (53·9–63·0) 60·6 (55·9–65·7) 59·8 (57·3–62·5) 63·6 (61·1–66·1) 92·9 (91·3–94·4)
Black‡ 83·1 (72·7–94·9) 69·6 (46·5–88·2) R 48·2 (29·9–66·4) R 60·0 (24·9–90·5) R 77·4 (22·6–100) R 66·9 (47·5–83·5) R 52·6 (34·9–69·7) R 78·7 (68·4–90·6)
White 85·4 (83·9–86·8) 59·9 (56·7–63·2) 64·9 (62·1–67·9) 57·8 (53·4–62·6) 60·5 (55·7–65·7) 59·3 (56·7–62·0) 64·0 (61·5–66·6) 93·1 (91·6–94·7)
New Jersey (all races), N 83·4 (82·7–84·1) 61·5 (60·1–62·9) 61·2 (59·9–62·6) 56·1 (54·1–58·3) 58·4 (56·4–60·6) 59·7 (58·6–60·9) 60·6 (59·5–61·7) 91·2 (90·4–91·9)
Black 73·1 (70·2–76·1) 51·6 (46·4–57·4) 51·5 (47·7–55·6) 46·4 (38·3–56·2) 45·1 (38·5–53·0) 50·3 (45·8–55·2) 50·3 (46·9–53·9) 81·0 (78·5–83·5)
White 83·8 (83·1–84·6) 61·4 (60·0–62·9) 61·8 (60·4–63·2) 56·0 (53·9–58·3) 58·9 (56·7–61·1) 59·6 (58·4–60·9) 61·1 (59·9–62·3) 90·8 (90·0–91·7)
(Continues on next page)
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See Online for webpanel
The proportion of survivors is constrained in the range 
zero to one (or 0 to 100%), but conﬁ dence intervals (CIs) 
for relative survival derived in the usual way, from the 
Normal approximation, can produce implausible values 
(<0 or >1). SEER*Stat provided the standard error of the 
cumulative relative survival based on the Greenwood 
formula,61 but did not provide CIs. We used these 
standard errors to estimate CIs on the logarithmic scale 
(webpanel).
For the USA, we constructed funnel plots of relative 
survival for each cancer and sex, to obtain further insight 
into the variability of survival by race and state, and to 
avoid spurious ranking of the survival estimates.62 The 
plots show how much a particular survival estimate 
deviates from the pooled US value, given the precision of 
each estimate. The precision depends on the number of 
deaths included in the analysis, which depends in turn 
on the size of the popu lation and the frequency and 
lethality of the cancer in that population. 5-year relative 
survival estimates for each popu lation, age-standardised 
and adjusted for race-speciﬁ c and state-speciﬁ c 
background mortality, were plotted against the precision 
of the estimates, taken as the inverse square of their 
standard errors (webpanel). The horizontal line in each 
plot, the target, was estimated as the pooled 5-year relative 
survival for all participating US populations, age-
standardised to the same weights. Raw survival esti mates 
were not plotted. The 99·8% control limits super imposed 
on each plot represent about three standard deviations 
from the pooled US survival at each level of precision.
Breast Colon Rectum Colorectum Prostate
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
Men RS (%) 
(95% CI)
Women RS (%) 
(95% CI)
RS (%) (95% CI)
(Continued from previous page)
New Mexico (all races), S 84·6 (82·8–86·4) 62·1 (58·1–66·3) 61·7 (57·9–65·7) 52·6 (47·2–58·7) 59·1 (53·0–65·8) 59·0 (55·8–62·4) 61·0 (57·8–64·4) 92·4 (90·7–94·2)
White 84·7 (82·8–86·6) 61·7 (57·7–66·0) 61·4 (57·5–65·6) 52·7 (47·1–58·9) 59·0 (52·8–65·9) 58·9 (55·6–62·4) 60·9 (57·6–64·4) 92·7 (91·0–94·4)
New York State (all 
races), N
81·0 (80·5–81·5) 56·8 (55·8–57·8) 56·5 (55·6–57·5) 55·0 (53·5–56·5) 56·7 (55·2–58·3) 56·3 (55·4–57·1) 56·7 (55·9–57·5) 85·9 (85·3–86·5)
Black 67·2 (65·4–69·1) 45·9 (42·8–49·2) 46·0 (43·5–48·6) 42·8 (37·6–48·7) 46·8 (42·2–51·9) 45·1 (42·4–47·9) 46·2 (44·0–48·5) 75·9 (74·2–77·7)
White 82·1 (81·5–82·6) 57·3 (56·2–58·4) 57·2 (56·2–58·2) 55·8 (54·2–57·4) 57·4 (55·8–59·1) 56·9 (56·0–57·8) 57·4 (56·5–58·2) 86·5 (85·8–87·2)
New York City, NY (all 
races), N
77·6 (76·8–78·4) 54·5 (52·9–56·2) 53·8 (52·3–55·3) 50·9 (48·4–53·5) 52·6 (50·2–55·1) 53·5 (52·1–54·9) 53·5 (52·3–54·8) 82·3 (81·2–83·4)
Black 65·8 (63·7–67·9) 45·2 (41·7–49·1) 45·0 (42·2–48·0) 44·4 (38·3–51·4) 46·5 (41·3–52·3) 45·0 (41·9–48·3) 45·3 (42·8–48·0) 74·0 (71·9–76·1)
White 79·6 (78·7–80·6) 55·6 (53·7–57·6) 54·9 (53·1–56·7) 51·9 (49·1–54·9) 53·3 (50·5–56·3) 54·5 (52·9–56·2) 54·5 (53·0–56·1) 83·3 (81·8–84·7)
Rhode Island (all races), N 84·6 (82·7–86·4) 64·7 (60·9–68·7) 63·4 (60·0–67·1) 60·1 (54·5–66·3) 59·9 (54·5–65·7) 63·4 (60·2–66·7) 62·7 (59·8–65·8) 90·9 (88·5–93·3)
Black‡§ 82·9 (65·8–100) 58·6 (28·5–85·9) R 45·0 (16·5–71·8) R NA 79·6 (28·8–100) R 65·5 (35·6–90·7) R 57·5 (31·4–78·5) R 75·5 (59·5–89·0) R
White 84·9 (83·1–86·8) 64·9 (61·1–69·0) 63·7 (60·2–67·4) 60·2 (54·5–66·4) 59·3 (53·9–65·3) 63·6 (60·4–66·9) 62·8 (59·8–65·9) 91·4 (89·0–93·9)
Seattle, WA (all races), S 88·7 (87·6–89·8) 63·9 (61·5–66·4) 64·2 (61·9–66·6) 60·8 (57·4–64·5) 65·5 (61·9–69·3) 63·2 (61·1–65·3) 64·9 (62·9–66·9) 95·3 (94·3–96·4)
Black 64·7 (55·5–75·3) 54·9 (42·5–71·0) 63·9 (45·4–80·2) R 46·9 (26·6–67·1) R 48·7 (20·1–75·1) R 51·9 (41·0–65·6) 54·9 (42·1–71·8) 89·6 (84·0–95·4)
White 89·3 (88·2–90·4) 64·4 (61·9–67·0) 64·1 (61·7–66·5) 61·7 (58·1–65·6) 65·7 (61·9–69·6) 63·8 (61·7–66·0) 64·8 (62·8–66·9) 95·4 (94·3–96·4)
Utah (all races), S 85·8 (84·0–87·7) 60·8 (56·8–65·1) 58·6 (54·5–63·0) 59·9 (54·2–66·2) 61·3 (55·0–68·2) 61·1 (57·8–64·6) 59·6 (56·2–63·3) 93·7 (92·1–95·2)
White 85·9 (84·0–87·9) 60·7 (56·6–65·1) 58·7 (54·6–63·2) 59·7 (53·8–66·2) 62·6 (56·3–69·8) 61·0 (57·6–64·6) 60·2 (56·6–63·9) 93·5 (91·9–95·1)
Wyoming (all races), N 84·2 (80·8–87·7) 59·5 (52·5–67·4) 58·5 (52·1–65·6) 46·4 (37·2–57·9) 52·2 (42·7–63·9) 55·9 (50·1–62·4) 57·7 (52·2–63·8) 92·2 (89·2–95·2)
White 84·3 (80·9–87·8) 60·5 (53·5–68·4) 58·1 (51·7–65·3) 46·2 (37·0–57·9) 52·5 (42·7–64·4) 56·5 (50·6–63·0) 57·5 (52·0–63·7) 92·1 (89·2–95·1)
NPCR (all races) 83·1 (82·8–83·4) 59·8 (59·3–60·4) 59·6 (59·1–60·1) 56·3 (55·5–57·1) 58·8 (58·0–59·7) 58·8 (58·3–59·2) 59·6 (59·1–60·0) 89·5 (89·2–89·8)
Black 70·7 (69·6–71·8) 52·1 (50·2–54·1) 50·5 (49·0–52·0) 46·9 (43·7–50·2) 49·1 (46·4–51·9) 50·7 (49·1–52·5) 50·3 (49·0–51·6) 81·1 (80·2–82·1)
White 84·0 (83·7–84·3) 60·1 (59·6–60·7) 60·4 (59·8–60·9) 56·7 (55·8–57·5) 59·4 (58·5–60·3) 59·1 (58·6–59·6) 60·2 (59·8–60·7) 90·0 (89·7–90·3)
SEER (all races) 86·1 (85·6–86·5) 61·9 (61·0–62·8) 62·1 (61·2–62·9) 58·5 (57·1–59·8) 61·8 (60·4–63·2) 60·9 (60·2–61·7) 62·2 (61·5–62·9) 93·1 (92·7–93·5)
Black 72·6 (70·8–74·5) 52·1 (48·9–55·5) 52·8 (50·2–55·5) 51·1 (45·8–56·9) 50·0 (45·1–55·6) 51·9 (49·2–54·9) 52·5 (50·2–55·0) 87·2 (85·7–88·7)
White 87·0 (86·6–87·5) 62·3 (61·3–63·3) 62·8 (61·9–63·8) 58·9 (57·5–60·4) 62·7 (61·2–64·2) 61·3 (60·5–62·2) 63·0 (62·2–63·8) 93·5 (93·0–93·9)
US registries (all races) 84·0 (83·8–84·2) 60·2 (59·8–60·6) 60·2 (59·8–60·6) 57·0 (56·4–57·6) 59·9 (59·2–60·5) 59·3 (58·9–59·6) 60·3 (60·0–60·6) 92·3 (92·1–92·5)
Black 70·9 (70·0–71·8) 51·5 (50·0–53·1) 51·0 (49·8–52·3) 47·4 (44·7–50·1) 49·4 (47·1–51·7) 50·5 (49·1–51·8) 50·8 (49·7–51·9) 85·8 (85·0–86·6)
White 84·7 (84·5–84·9) 60·5 (60·0–60·9) 60·8 (60·4–61·2) 57·3 (56·6–57·9) 60·4 (59·7–61·1) 59·6 (59·2–59·9) 60·8 (60·5–61·2) 92·4 (92·2–92·7)
RS=relative survival. S=Surveillance, Epidemiology and End Results (SEER) registry. N=National Program of Cancer Registries (NPCR) registry. See text for attribution of registries to NPCR and SEER.
R=raw (not age-standardised) survival estimate: too few cases in one or more age groups. *International Cancer Survival Standard (see text). †95% CIs were calculated by use of a logarithmic transformation (see 
text). ‡Survival truncated if greater than 1·0 (100%). §Survival estimates based on fewer than ﬁ ve patients are not shown (NA=not applicable). Black populations are not shown separately for Hawaii, Idaho, New 
Mexico, Utah, or Wyoming, because it was not possible to estimate relative survival for blacks in these states with race-speciﬁ c life tables (see text).
Table 3: 5-year relative survival (%) by use of state-speciﬁ c and race-speciﬁ c life tables and age-standardised to ICSS weights* with 95% CIs† for adults (aged 15–99 years) diagnosed with 
cancer of the breast (women), colon, rectum, or prostate during 1990–94 and followed up to Dec 31, 1999, by race: US populations
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Diﬀ erences between survival estimates are presented as 
the absolute value, eg, 15% is given as 5% (not 50%) higher 
than 10%.
We analysed individual data for almost 2 million adults 
who were diagnosed with a ﬁ rst, primary, malignant, 
invasive neoplasm of the breast (women), colon, rectum, 
or prostate during the period 1990–94 and who had been 
followed up to ascertain their vital status for at least 5 years 
after diagnosis until the end of 1999 or later. Data were 
contributed by 101 population-based cancer regis tries 
covering a combined population of almost 300 million 
persons living in 31 countries (table 1 and webﬁ gure 1). 
Canada and the USA contributed 1·07 million patients 
(54% of the total) from a population base of 125 million. 
The 24 European countries contri buted 740 000 patients 
(37%) from a population base of 126 million, indicating 
lower mean incidence of cancer than in North America.
The smallest dataset came from Sétif (Algeria), covering 
a population of 1·1 million, some 4% of the national popu-
lation. The registry could only provide data for the period 
1992–94, the population is young, and cancer risks are 
currently low on the global scale.63 The dataset was there-
fore small, a total of 300 patients. This decreases the 
statistical precision of survival estimates, but no patient was 
detected solely at death certiﬁ cation or autopsy, and the 
vital status of every patient was ascertained at a home visit 
by registry staﬀ , something no other registry could deliver. 
Some of the datasets for black patients in US states were of 
similar size (webtable). California provided the largest 
single dataset of 240 000 patients diagnosed during 1990–94 
in a population of 31 million (12% of the US population), 
with a very high cancer risk on the global scale (table 1).
For 16 of the 31 countries, the data covered 100% of the 
national population (table 1). The proportion of the national 
population covered by the data for the other 15 countries 
ranged from less than 10% (Algeria, Brazil, Japan, Austria, 
Czech Republic, France, Germany, Poland) to 10–29% 
(Italy, Portugal, Spain, Switzerland) and 30% or more 
(Canada, USA, the Netherlands).
Most registries provided data on patients diagnosed 
during the entire 5-year period 1990–94, but ten registries 
provided data for shorter periods (table 1).
Data for all four index cancers were provided by 89 of the 
101 registries. Two specialised registries in Côte-d’Or 
(France) only collect data on cancers of the breast or 
colorectum, respectively, whereas ten general registries 
that collect data for all cancers only contributed data for 
selected cancers: breast (Isère, France; northern Nether-
lands; all ﬁ ve Swiss registries); breast, colon, and prostate 
(Campinas, Brazil; Nova Scotia, Canada), or breast, colon, 
and rectum (Granada, Spain; table 1).
Ethical approval for the CONCORD study33 was obtained 
from the Istituto Superiore di Sanità, Rome, Italy (CE-ISS 
02/03, May 20, 2002) and from the Institutional Review 
Board of the CDC, Atlanta, GA, USA (IRB #3551, July 24, 
2002). SEER data were obtained from the public-use 
dataset.38 For other registries, anonymised data were trans-
mitted to the CONCORD Data Analysis Centre at the 
Istituto Superiore di Sanità by use of special courier 
delivery of encrypted and password-protected CD-ROMs 
with separate email transmission of the password, or pre-
planned deposition of password-protected ﬁ les on a 
specially created File Transfer Protocol (FTP) site from 
which the data were immediately removed in Rome. Each 
tumour record included a serial number for the purposes 
of quality control with the originating cancer registry.
Role of the funding source
The pilot study (January, 2000 to March, 2000) was funded 
by the UK Department of Health (£75 000). The CDC 
funded data collection and the costs of linkage to the 
National Death Index for the phase I study in participating 
registries in the National Program of Cancer Registries 
(US$3 million). The Cancer Survival Group (including BR, 
MQ) in the London School of Hygiene and Tropical 
Medicine, London, UK, has been funded by Cancer 
Research UK (grant C1336/A5735) since April, 2005. Fund -
ing applications were open and competitive. None of the 
funding sources had any role in design, data collection, 
ana lysis, interpretation of the data, or writing of this article. 
MPC, MQ, RdA, RC, SF, MSantaquilani, and AV had 
access to the raw data. The corresponding author had full 
access to all of the data and the ﬁ nal responsibility to 
submit for publication.
Results
The background risk of death in the general population 
varied widely between the participating countries and 
regions. The mean life expectancy at birth during the 
decade 1990–99 ranged from 63·7 to 77·6 years in men 
and from 70·9 to 83·7 years in women.46 In the USA, the 
range of life expectancies in white and black populations 
did not overlap at all in the states and metropolitan areas 
for which life tables could be con structed for both groups. 
The ranges for men were 64·0–70·1 years in blacks and 
71·1–75·9 years in whites, whereas the ranges in women 
were 73·3–76·5 years in  blacks and 78·8–80·9 years in 
whites. 
The cumulative risk of death from all causes over the age 
range 15–59 years in the general population of the partici-
pating countries and regions ranged widely, from 9% to 
34% in men and from 5% to 17% in women. Over the age 
range 60–84 years, the cumulative risk of death ranged from 
60% to 86% in men and from 40% to 75% in women.46
Of 785 255 records of breast cancer submitted for 
analysis, 45 020 (6%) related to women registered with a 
previous primary cancer, and were excluded (available on-
line34) Of the 740 235 eligible ﬁ rst primary invasive breast 
cancers, 9215 records were excluded as death-certiﬁ cate-
only (DCO) registrations (1%), 239 as autopsy-detected 
tumours (<1%) and 2064 with major errors (<1%), leaving 
728 717 patients for analysis (98% of those eligible), of 
whom 370 000 (51%) were resident in North America and 
304 000 (42%) in Europe (table 1). Almost all (97%) of the 
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tumours included in the analyses were microscopically 
veriﬁ ed, less than 1% of patients were censored from the 
analysis within 5 years of diagnosis, and 2·3% died within 
1 month of diagnosis.
Relative survival at 5 years, age-standardised to the 
International Cancer Survival Standard weights, ranged 
from 80% or over in North America, Sweden, Japan, 
Finland, and Australia to less than 60% in Brazil and 
Slovakia, and below 40% in Algeria (table 2 and ﬁ gure 1). 
Survival in the 24 European countries that contributed to 
CONCORD was mostly in the range 70–79%.
The survival estimate of 38·8% (95% CI 31·4–46·2) for 
Sétif (Algeria) is based on 180 patients, and it is not age-
standardised because there were too few patients for 
analysis in some age groups, but age-standardisation 
for breast cancer in other datasets rarely altered the raw 
estimate by more than 5% in either direction (data not 
shown), and survival from breast cancer was undoubtedly 
much lower in Algeria than in all the other countries.
The pooled estimate of 5-year survival for the two 
Brazilian registries was 58·4%, but the estimate for 
Goiânia (65·4%) is more reliable than the very low ﬁ gure 
for Campinas (36·6%), where high proportions of patients 
were excluded as DCO or with major errors (available 
online34). The propor tion of metastatic tumours was higher 
in Campinas, however. The 5-year survival estimate for 
Cuba was 84·0%, but this was likely to be an over-estimate: 
some 28% of records were excluded because they were 
registered solely from a death certiﬁ cate.
The pooled estimate of 5-year survival for Canada was 
82·5%, with a narrow range from 79·3% in Nova Scotia to 
85·4% in British Columbia (table 2 and ﬁ gure 1). In the 
USA, 5-year relative survival for all races combined ranged 
from 78–81% in New York City, New York State, and 
Louisiana to 89–90% in Hawaii and Seattle, WA (table 2), 
but most of the estimates were within a fairly narrow 
range, from 82% to 87% (ﬁ gure 2). Survival in metropolitan 
areas covered by SEER registries was similar to that in the 
respective states: Detroit, MI 83·0% and Michigan State 
82·3%; San Francisco, CA 86·2% and California 
State 84·6%. 5-year survival was 77·4% for residents of 
New York City, NY (with 40% of the state population), 
slightly lower than for New York State as a whole, 81·0%.
Survival was lower for blacks than for whites in all 
17 populations in the USA for which this could be assessed 
with race-speciﬁ c life tables (webﬁ gure 2). The age-adjusted 
pooled estimate of 5-year survival was 84·7% for whites 
(range 80–90%) and 70·9% for blacks (table 3). The range 
in survival was wider for blacks (60–83%), but the values at 
both extremes of the range were based on relatively few 
patients and have wider CIs. Within a given US population, 
the absolute diﬀ erence in age-adjusted relative survival be-
tween blacks and whites ranged from 2% (Rhode Island, 
Nebraska) to 25–27% (Iowa and Seattle, WA; table 3 and 
webﬁ gure 2). Even in areas where blacks comprise 25% or 
more of the population, survival for black women was 
8–14% below the lowest estimate for white women (79·6%) 
in any of the participating areas: Atlanta, GA (71·1%), 
Detroit, MI (71·7%), New York City, NY (65·8%), and 
Louisiana (69·9%). The pooled estimate of 5-year survival 
for the USA was 84·0%, with 86·1% in areas covered by 
SEER and 83·1% in areas covered by NPCR (table 3).
Survival in black women was always lower than the mean 
survival for all US populations included, and often more 
than three standard deviations below it (below the 99·8% 
control limits), after controlling for the precision of the 
estimates. Survival in white women is generally within or 
above the upper control limits, especially in territories 
covered by the SEER Program. A notable exception is for 
white women in New York State, including New York City, 
where the survival estimates are precise, but well below the 
lower control limits (webﬁ gure 3).
The pooled estimate of 5-year survival for breast cancer 
in Japan was 81·6%. Survival in Osaka (79·4%) was lower 
than in Fukui (83·1%) and Yamagata (87·3%; table 2 and 
ﬁ gure 1).
5-year relative survival for breast cancer in Europe, age-
standardised to the ICSS weights, ranged from 57·9% in 
Slovakia to 82·0% in Sweden (table 2 and ﬁ gure 1), whereas 
the pooled estimate derived from the data of 58 registries 
in the 24 participating European countries was 73·1%. 
Survival estimates for most of these countries have been 
reported.27 The CONCORD study includes additional data 
from four countries: 5-year survival was 69·6% in Ireland 
and 72·0% in Northern Ireland, similar to the UK 
mean value of 69·7% (table 2). In Switzerland, 5-year 
survival in the cantons of St Gallen-Appenzell, Grau-
bunden-Glarus, and Valais was 72–75%, about 4–7% lower 
than in Geneva or Basel. 5-year survival was 77·8% in 
northern Netherlands, similar to that in Amsterdam and 
southern Netherlands (76–78%).
The national estimate of 5-year survival for breast cancer 
in Australia was 80·7%. Survival was virtually identical 
in the six largest states (96% of the national population), in 
the range 80–82%, but notably lower in the two smallest 
regions: 71·9% in Northern Territory (1·0% of the 
population) and 77·1% in Tasmania (2·6%).
Of 488 741 colon cancer records submitted for analysis, 
45 862 records (9%) were excluded for a previous cancer, 
leaving 442 879 ﬁ rst, primary, invasive colon cancers 
eligible for analysis (available online34). A further 13 102 (3%) 
were excluded as DCO registrations, 1534 (<1%) as autopsy-
detected tumours, and 1144 (<1%) as major errors, leaving 
427 099 patients for inclusion in the analyses (96% of those 
eligible). Of these, 214 000 (50%) were resident in North 
America, 170 000 (40%) in Europe, and 30 300 (7%) in 
Australia. Cancers of the colon comprised 67% of all 
colorectal tumours (table 1). Microscopic veriﬁ cation was 
high (94%), and less than 1% of patients were censored 
from the analysis within 5 years of diagnosis. Almost 11% 
of patients died within the ﬁ rst month after diagnosis.
Relative survival at 5 years, age-standardised to the ICSS 
weights, ranged from about 60% in North America, Japan, 
Australia, and some western European countries down to 
See Online for webﬁ gures 2 and 3
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40% or less in Algeria, Brazil, Czech Republic, Estonia, 
Poland, Slovenia, and Wales (table 2 and ﬁ gure 3).
The survival estimates of 11·4% (95% CI 0·7–40·9) for 
men and 30·6% (9·5–56·1) for women in Sétif (Algeria) 
were based on fewer than 20 patients, and are not age-
standardised, but survival was clearly lower in Algeria than 
in all the other countries.
The estimate of 5-year relative survival for Goiânia 
(48·1% in men, 44·8% in women) was more plausible for 
Brazil than the low estimates for Campinas, where 26% of 
patients had to be excluded with errors.34 5-year survival in 
Cuba was about 60% in both sexes, although more than 
half the patients were excluded from analysis as DCOs.34 
In Canada, the pooled estimate of 5-year survival was 
56·1% for men and 58·7% for women. Variation between 
provinces was small, from 54–57% in men and 58–60% 
in women (table 2 and ﬁ gure 3). In the USA, 5-year 
relative survival for all races combined was 60·1% in both 
sexes, with a range from 53·6% for women in New York 
City to 67·9% for men in Hawaii (table 2 and ﬁ gure 
2). Again, most of the estimates were within a narrow 
range, 59–64%.
5-year survival for colon cancer among blacks in the USA 
was lower than among whites. In 34 paired observations of 
this diﬀ erence in survival (men and women in 17 popu -
lations), only three exceptions were noted, in men and 
women in Iowa and men in Nebraska. The estimates for 
blacks in those three areas were based on fewer than 
50 patients, have wide conﬁ dence intervals and were not 
age-standardised (table 3 and webﬁ gure 4). The pooled 
estimate of age-adjusted 5-year relative survival for the 
USA was 61% for white men and women, and 51–52% for 
black men and women. Within a given population, the 
absolute diﬀ erence between blacks and whites ranged from 
2·6% in men and 7·3% in women in Los Angeles, CA to 
14·3–17·2% in Colorado. The geographical range in 
black–white diﬀ erences in survival is aﬀ ected by small 
populations to some extent, but even in areas where blacks 
comprise 25% or more of the population (Atlanta, GA, 
Detroit, MI, New York City, NY, Louisiana), 5-year survival 
from colon cancer in blacks was 6–12% lower than for 
whites in the same population (table 3). The pooled 
estimate of 5-year survival in areas covered by NPCR was 
59·8% for men and 59·6% for women, and 61·9% for men 
and 62·1% for women in SEER areas.
Age-standardised survival in whites ranged from 54·9% 
to 67·9% (table 3 and webﬁ gure 4). The range of age-
standardised survival for blacks was 45·0% to 59·9%. 
Survival in blacks was generally lower than the mean value 
for all included US populations and often more than three 
standard deviations below the mean, after controlling for 
precision of the survival estimates. Survival in whites was 
generally within the control limits. The main exception 
was for white women in New York State, including New 
York City, NY, where survival estimates were precise, but 
more than three standard deviations below the lower control 
limits around the pooled US estimate (webﬁ gure 3).
In Japan, the pooled survival estimate was 63·0% in 
men and 57·1% in women, although survival was about 
10% lower in Osaka prefecture than in Fukui or Yamagata 
(table 2 and ﬁ gure 3).
In Europe, 5-year relative survival for colon cancer in 
men ranged from 28·5% in Poland to 54–57% in Spain, 
Finland, Austria, and France. In women, the lowest 
estimate was also for Poland (30·9%), while survival was 
in the range 55–60% in nine countries (table 2 and 
ﬁ gure 3). The pooled estimates for the 51 contributing 
registries in 23 European countries were 46·8% in men 
and 48·4% in women. Data on colon cancer were not 
available for the ﬁ ve Swiss registries, Isère (France), or 
northern Netherlands. Survival estimates for most of 
these countries have been published elsewhere.27 This 
study included additional data from two countries. 5-year 
survival in Ireland was 49·1% in men and 48·5% in 
women. The estimates for Northern Ireland were 47·3% 
in men and 49·0% in women, slightly higher than the 
pooled estimate for the UK, 43·5% in men and 44·4% in 
women (table 2).
The national estimate of 5-year survival for colon cancer 
in Australia was 57·8% in men and 57·7% in women. 
Survival ranged from 50–62% in the eight states and 
territories: it was highest in New South Wales, the 
Australian Capital Territory, and Queensland, and lowest 
in Tasmania, Northern Territory, and Western Australia 
(9·6% of the population; table 1).
Of 233 176 rectal-cancer records submitted for analysis, 
15 731 records (7%) were excluded for a previous cancer, 
leaving 217 445 ﬁ rst, primary, invasive rectal cancers eligible 
for analysis (available online34). A further 3213 (1%) were 
excluded as DCO regis trations, 517 (<1%) as autopsy-
detected tumours and 574 (<1%) as major errors, leaving 
213 141 patients for inclusion in the analyses (98% of those 
eligible). Of these, 83 000 (39%) were resident in North 
America, 106 000 (50%) in Europe, and 16 800 (8%) in 
Australia. Cancers of the rectum comprised 33% of all 
colorectal tumours (table 1). Micro scopic veriﬁ cation was 
high (96%). Less than 1% of patients were censored from 
the analysis within 5 years of diagnosis. Almost 8% died 
within the ﬁ rst month after diagnosis.
5-year relative survival from rectal cancer, age-
standardised to the ICSS weights, ranged from about 60% 
to around 20% in both sexes, with Japan, Canada, the 
USA, France, the Netherlands, Sweden, and Australia at 
the upper end of the range, and Algeria, Estonia, Poland, 
and Slovakia at the lower end (table 2 and ﬁ gure 3).
The 5-year survival estimates of 25·9% (95% CI 
11·4–43·7) for men and 18·2% (6·6–34·6) for women in 
Sétif (Algeria) were each based on 30 patients, and were 
not age-standardised because data were too sparse in some 
age groups.
5-year relative survival in Goiânia, Brazil, was 49·3% in 
men and 38·4% in women. No data were available for 
Campinas. 5-year survival in Cuba was 59·2% in men and 
62·8% in women, based on analysis of about 700 patients 
See Online for webﬁ gure 4
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Figure 3: 5-year relative 
survival (%), age-
standardised to the ICSS 
weights* with 95% CIs for 
adults (aged 15–99 years) 
diagnosed with cancer of the 
colon or rectum during 
1990–94 and followed up to 
Dec 31, 1999: country
Vertical bar on the right of 
each graphic shows the 
contribution (%) of each 
continent to the total number 
of cases analysed 
(contributions under 1% are 
not labelled). Red vertical line 
represents mean survival for 
the 22 European countries 
that participated in 
EUROCARE-3, age-
standardised to the ICSS 
weights. *Age-standardised to 
ICSS weights, except for Sétif, 
Algeria (all cancers), Austria 
(rectum [women]), Iceland 
(rectum [men and women]), 
Ireland (rectum [women]), 
Malta (colon [men] and 
rectum [men and women]), 
which were unstandardised 
values (see text). †Problems 
with data quality might have 
led to over-estimation (see 
text). 
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in each sex, although 782 (36%) patients had been excluded 
as DCO (available online34).
In Canada, the pooled estimate of 5-year survival was 
58·7% for women and 53·1% for men, slightly lower in 
the global range than for cancers of the breast, colon, or 
prostate in Canada. Survival in men ranged from 51·1% 
(Ontario) to 64·6% (British Columbia), and from 57·8% to 
62·8% in women. In the USA, 5-year relative survival for all 
races combined was 56·9% in men and 59·8% in women, 
with a range from 46–67% in men and 52–66% in 
women (table 2 and ﬁ gure 2). Again, most of the estimates 
were within a narrow range, from 55–60%  in men and 
57–62% in women. By contrast with colon cancer, survival 
from rectal cancer was slightly higher in women than in 
men.
5-year survival for rectal cancer in the USA was generally 
lower for blacks than for whites, in both sexes (webﬁ gure 4). 
The overall estimate of 5-year survival in men was 47·4% 
for blacks and 57·3% for whites; for women, the estimates 
were 49·4% for blacks and 60·4% for whites (table 3). 
When survival for blacks was above 60%, or higher than 
for whites in the same population (Colorado, Connecticut, 
Nebraska, Rhode Island), the estimates for blacks were 
based on around 50 or fewer patients, with wide CIs, and 
were usually not age-standardised (table 3 and webﬁ gure 4). 
Even where blacks comprised 25% or more of the 
population (Atlanta, GA, Detroit, MI, New York City, NY, 
Louisiana), 5-year survival was 6–16% lower than for 
whites in the same area. The pooled estimate of 5-year 
survival in areas covered by NPCR was 56·3% for men 
and 58·8% for women, some 2–3%  lower than for SEER 
areas (58·5% men, 61·8% women; table 3 and ﬁ gure 2).
5-year survival ranged from 46·2% to 67·9% in whites; 
in blacks, the range of age-standardised survival was from 
42·8% to 63·5% (table 3 and webﬁ gure 4). Survival in 
blacks was generally lower than the mean value for all 
included US populations, although more often within the 
control limits. Survival for whites was also generally within 
the control limits, with the exception of New York City, NY, 
where survival was below the control limits (webﬁ gure 3).
In Japan, the pooled survival estimate for colon cancer 
was 58·2% for men and 57·6% for women, although 
survival was lower in Osaka (54–55%) than in Fukui or 
Yamagata (60–64%; table 2 and ﬁ gure 3).
In Europe, the geographical pattern for age-standardised 
5-year survival was similar to that for colon cancer. For 
men, the range was from 28–30% in Poland, West 
Bohemia (Czech Republic), and Slovakia to 53–55% in 
France, Sweden, and the Netherlands; whereas for 
women, the range was from 30–32% in Poland, Estonia, 
and Slovakia up to 63·9% in France, where three of the 
four contributing registries ranked the highest in Europe 
(table 2 and ﬁ gure 3). The pooled estimates for the 
51 contributing registries in 23 Euro pean countries were 
43·2% in men and 47·4% in women. Data on rectal 
cancer were not available for Isère (France), northern 
Netherlands, or the ﬁ ve Swiss regis tries. 5-year survival 
in Ireland was 41·1% in men and 52·5% in women. The 
estimate for women is not age-standardised, but it is 
based on over 200 patients (table 1), and similarity 
between the raw and standardised estimates for cancers 
of the colon and colon and rectum combined (less than 
1%, data not shown) suggests that an age-standardised 
estimate for rectal cancer would not have been very 
diﬀ erent. In Northern Ireland, the estimates were 48·2% 
in men and 43·8% in women (pooled UK estimates were 
40·6% in men and 45·3% in women; table 2).
The national estimate of age-standardised 5-year survival 
for rectal cancer in Australia was 54·8% in men and 59·2% 
in women. Survival ranged from 45–57% in men and from 
55–61% in women.
Of 663 621 men with prostate cancer, 35 934 (5%) were 
ex cluded for a previous cancer, leaving 627 687 eligible ﬁ rst, 
primary, invasive cancers of the prostate (available online34). 
After 11 163 (2%) exclusions for DCO, 1640 (<1%) for 
autopsy-detection and 801 (<1%) for major error, 
614 083 men were included in the analyses (98% of those 
eligible). Of these, 403 000 (66%) were resident in North 
America, 162 000 (26%) in Europe, and 43 000 (7%) in 
Australia (table 1). Microscopic veriﬁ cation was available 
for 96% of the tumours. Less than 1% of men were cen-
sored from the analysis within 5 years of diagnosis, but 
3·2% died within 1 month of diagnosis.
5-year relative survival, age-standardised to the ICSS 
weights, ranged from 80% or higher in the USA (92%), 
Canada and Austria to less than 40% in Denmark, Poland, 
and Algeria (table 2 and ﬁ gure 1).
The 5-year survival estimate of 21·4% (95% CI 8·7–38·9) 
in Sétif (Algeria) was based on 36 patients, and was not 
age-standardised.
In Brazil, 5-year survival was 34·4% in Campinas and 
55·7% in Goiânia. Some 30% of tumour records in 
Campinas were excluded with major errors. Notably, 
20 (13·4%) men in Campinas and 71 (21·8%) men in 
Goiânia died within 1 month of diagnosis, which are the 
highest proportions of any of the participating registries 
(available online34). 5-year survival in Cuba was 69·7% 
(table 3). This estimate was based on 4300 patients, but 
54% of the original data set of 9500 patients had been 
excluded as DCO (table 1 and data available online34).
The pooled estimate of 5-year survival for prostate cancer 
in Canada was 85·1%, ranging from 77·5% in Saskatchewan 
to 89·3% in British Columbia (table 2 and ﬁ gure 1). In the 
USA, 5-year relative survival from prostate cancer was 
91·9% for all races combined, with a range from 81·6% in 
New York City, NY up to 95·0% in Seattle, WA (table 2 and 
ﬁ gure 2), but most of the estimates were within a fairly 
narrow range, from 88·6% (Louisiana) to 94·0% (Atlanta, 
GA). The relative survival estimate for the state of Michigan 
was 100%, although in the city of Detroit, MI, with 42% of 
the state population (webtable), survival from prostate 
cancer in the same period was 93·8%.
Age-standardised 5-year relative survival for prostate 
cancer in blacks was lower than for whites in all 
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populations for which this could be separately assessed 
with race-speciﬁ c life tables (webﬁ gure 2). The overall 
estimate of 5-year survival was 85·8% for blacks and 
92·4% for whites, with an overall diﬀ erence of 6·6% 
(table 3). The diﬀ erence in survival between blacks and 
whites ranged from 5·0% (Florida) to 14–16% (Nebraska, 
Rhode Island), and although the largest diﬀ erences arise 
where the black populations are smallest, each survival 
estimate was based on at least 70 patients (webtable). 
Survival in whites ranged from 83·3% (New York City, 
NY) to 96·1% (Atlanta, GA), and in blacks from 74·0% 
(New York City, NY) to 89·6% (Seattle, WA). The pooled 
estimate of 5-year survival was 89·5% in areas covered 
by NPCR, and 93·1% in SEER areas (table 3).
Survival in blacks was usually lower than the pooled US 
estimate, and often more than three standard deviations 
below it, after controlling for precision (webﬁ gure 3). 
Survival in whites was generally within the control limits. 
5-year survival for whites was above the upper 99·8% 
control limit in three SEER populations (Atlanta, GA, 
Seattle, WA, and Detroit, MI). Survival in whites was below 
the lower control limit in four NPCR populations, but for 
California and Florida the diﬀ erence was small (2–3%). In 
New York State, including New York City, NY, survival 
estimates are precise, but 6–9% below the pooled US 
estimate of 92·3% and well below the lower control limit 
(webﬁ gure 3).
The 5-year relative survival estimates for Michigan State 
(100% in both blacks and whites) were too high, and they 
are not shown in webﬁ gure 3, although the data were 
included in the pooled estimate. Information about the 
death had not been linked to the tumour record for some 
of the apparent 5-year survivors from prostate cancer in 
Michigan State, leading to an inﬂ ated estimate. This error 
did not aﬀ ect the survival estimates for prostate cancer in 
Detroit, MI or those for other cancers in Michigan State.
The pooled estimate of 5-year survival in Japan was 
50·4%, much lower on the global scale than for cancers of 
the breast, colon, or rectum in Japan. Survival estimates 
were similar in all three prefectures (table 2 and ﬁ gure 1).
The range of 5-year survival in Europe was especially 
wide for prostate cancer, from less than 40% in Poland and 
Denmark to more than 80% in Austria (table 2 and ﬁ gure 1). 
The pooled estimate for the 49 contributing registries in 23 
European countries was 57·1%. Data were not available for 
nine registries: Switzerland (ﬁ ve registries), Isère and Côte 
d’Or (France), Granada (Spain), and northern Netherlands. 
5-year survival in the Ireland was 62·8%. In Northern 
Ireland, the estimate was 54·0%, slightly higher than the 
pooled estimate of 51·1% for the UK (table 2).
The national estimate of age-standardised 5-year 
survival for prostate cancer in Australia was 77·4%. 
Survival was closely similar in the six largest states, in 
the range 76–80%, but notably lower in the two smallest 
regions: 63·7% in Northern Territory (based on 
78 patients, estimate not age-standardised) and 70·2% in 
Tasmania (1321 patients).
Discussion
To our knowledge, the CONCORD study is the ﬁ rst attempt 
to provide directly comparable data on cancer survival from 
many countries around the world by use of central quality-
control procedures, standard analytic methods, and a 
single, centralised analysis of individual tumour records 
from population-based cancer registries. The ﬁ ndings 
should eventually complement the inter national data series 
on cancer incidence63,64 and mortality65–67 that have been 
available for several decades. Cancer-mortality statistics 
have often been used for international comparisons of pro-
gress against cancer,68–72 but they are also aﬀ ected by well-
known problems of comparability, both between countries 
and between successive revisions of the ICD.72–75 The 
ﬁ ndings presented here should help joint consideration of 
trends in incidence, survival, and mortality as indicators of 
cancer control. None of these indicators is perfect, but 
none is adequate on its own.76–78
Around 2800 life tables were created to enable the esti-
mation of relative survival by age, sex, country, and race.46 
The life tables are available on the CONCORD website.34
5-year relative survival for breast, colorectal, and prostate 
cancers was generally higher in North America, Australia, 
Japan, and northern, western, and southern Europe, and 
lower in Algeria, Brazil, and eastern Europe.
Exclusions for a previous cancer (5–9%) were not un-
expected. Population-based cancer survival analyses are 
usually restricted to patients with a ﬁ rst, primary invasive 
cancer, therefore, to the extent that patients with a previous 
cancer have been completely excluded in this study, this 
improves the comparability of the ﬁ ndings with other 
studies. Participating registries began operation between 
1950 and 1990. The data from newer registries are more 
likely to include unrecognised second and subsequent 
cancers, because any previous cancer(s) in a given patient 
might have been diagnosed before the registry began 
operation.
The main indices of data quality for cancer survival are 
the proportions of registered patients known to the registry 
by DCO, or lost to follow-up, and histologically veriﬁ ed. 
Data quality varied between registries (available online34), 
but was high overall: very few records were excluded with a 
major error. Exclusions for major errors were high in Cam-
pinas, Brazil (26–47%). The overall proportion of patients 
who died within 1 month of diagnosis was low for breast 
cancer (2·3%) and prostate cancer (3·2%), but higher for 
colon (10·9%) and rectal cancers (7·8%). These values 
varied between registries, but the overall pattern is plaus-
ible;  up to a third of colorectal cancers present as an emer-
gency with bowel obstruction. Fewer than 1% of patients 
were censored from the analysis within 5 years of 
diagnosis.
Three registries were excluded after quality control, 
because of high losses to follow-up or ineﬃ  cient regional 
or national linkage of information on the deaths of patients 
with cancer. The data for three other registries, Cuba, 
Campinas (Brazil) and, for prostate cancer, Michigan State 
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(USA), are less reliable than those from other registries, 
although for diﬀ erent reasons, discussed below. As with 
the ﬁ rst global compilation of cancer incidence data, in the 
1960s, retention of the two registries from Central and 
South America was partly prompted by the paucity of 
information on cancer survival from that region: “in this 
situation, even incomplete data have value”.64
Overall, the exclusion of DCO registrations accounted 
for only 1% (9215) of the eligible records for breast cancer, 
3% (13 102) for colon cancer, 1% (3213) for rectal cancer, and 
2% (11 163) for prostate cancer (available online34). The per-
centage was less than 1% in Algeria, USA, Canada, and 
Australia, and in the range 0–5% in most European coun-
tries and in Brazil, but higher in Osaka (Japan; 5–22%),79 
south Thames (UK); 10–16%), and Cuba (28–60%).80
The proportion of DCOs is not particularly useful as a 
comparative index of data quality,81 but a high proportion 
of DCO records does suggest that routine data-collection 
systems might not be complete. The relevance of this 
index also varies with the system of data collection. 
Sweden does not use DCOs because the registration of 
patients with cancer at the time of diagnosis is close to 
100%; by contrast, hospitals in Cuba are not allowed 
to retain the clinical records of deceased persons for more 
than 5 years.80
The diﬀ erent proportions of DCO records are unlikely to 
explain the diﬀ erences in survival between Europe and 
North America, however. The survival of patients whose 
tumour is registered as a DCO is generally lower than the 
mean for all registered cancer patients,82 so if they could 
have been included, the transatlantic diﬀ erences in survival 
would have been slightly greater. Furthermore, most DCO 
records in the European data are for patients aged 75 years 
or over,43 where the survival diﬀ erences are in any case 
more marked.9 By contrast, if a high proportion of DCO 
records is taken to suggest under-registration of long-term 
survivors, this might produce lower survival esti mates. 
Adjustment for both DCOs and incompleteness of 
registration in Thames (UK) and Finland had surprisingly 
little eﬀ ect on survival, however, even when 10–20% of 
registrations were DCOs, because the two corrections 
tended to oﬀ -set one another.83 Under-reporting of incident 
tumours by up to 5% has been shown not to aﬀ ect 
international comparisons of survival greatly.84
A plateau was imposed on the relative survival curve at 
some point during the ﬁ rst 5 years after diagnosis in about 
7% of the 6500 age-speciﬁ c survival estimates by registry, 
cancer, sex, and race (data not shown). The eﬀ ect on the 
age-standardised survival estimates at national level was 
almost always less than 1%.
Diagnostic variability between pathologists might contri-
bute to international diﬀ erences in cancer survival. Thus, 
survival from colorectal cancer in Japan is among the highest 
reported here, especially for men. In western countries, 
invasive colorectal carcinoma is diagnosed when neoplastic 
tissue invades beyond the submucosa of the bowel. Severe 
cytological or architectural changes conﬁ ned to the mucosa 
(in situ or intramucosal carcinoma) have no metastatic 
potential, and are often labelled high-grade dysplastic aden-
oma. Japanese pathologists rely more on cytological fea-
tures, however, and do not consider evidence of invasion 
into the submucosal layer as a mandatory requirement for 
the diagnosis of colorectal carcinoma.85 Pathological practice 
on this issue might vary substantially between western 
pathologists. Islands of dysplastic tissue might also be 
displaced or herniated beyond the muscularis mucosae 
without implying invasive potential (pseudo-invasion), and 
diﬀ erential diagnosis can be very diﬃ  cult.86,87
Assessment of the extent to which international survival 
diﬀ erences might be attributable to diﬀ erences in the 
pathological deﬁ nition of disease would need blinded 
review of pathological diagnoses of a sample of patients by 
an international panel of expert pathologists. Such reviews 
are invaluable, but rare.88
Survival in Sétif (Algeria) was the lowest of all the popu-
lations in the CONCORD study for each cancer. Even though 
the dataset was small, and covers only 4% of the national 
population, there is little doubt that survival in Algeria is 
very low. The age distribution of patients was younger than 
in most populations (available online34) and it cannot 
explain the low overall survival. Survival in Sétif was similar 
to or even lower than survival in blacks diag nosed during 
1993–97 in Harare, the Zimbabwean capital, where the very 
low survival was attributed to inade quate access to facilities 
for early diagnosis, clinical investigation, and treatment.89
Survival in the two Brazilian registries was generally low, 
although rectal-cancer survival in Goiânia was close to the 
European mean. Data quality issues prevented the 
inclusion of data from three of the 20 population-based 
registries in state capitals: these registries should be used 
to provide a broader picture of cancer survival in Brazil. 
Relative survival reported here for patients with cancer 
diagnosed in Cuba during 1990–94 was about 20% higher 
than estimates for those diagnosed during 1988–89, just a 
few years earlier.80 Cancer survival for children diagnosed 
in Cuba during 1988–89 was lower than in more developed 
countries.90 The high proportion of DCOs in the 1988–89 
data was considered less likely to be biased with respect to 
survival than in other registries, because of the way data 
were collected,80 but the survival estimates for Cuba 
reported here are still likely to be considerably inﬂ ated, and 
should be interpreted accordingly.
National estimates of survival for patients with cancer 
diagnosed in Japan during 1993–96 were slightly higher 
than the estimates for 1990–94 reported here.79 They were 
based on data from seven prefectures, including the three 
reported here (Yamagata, Fukui, and Osaka). As in the 
CONCORD data, survival in Osaka was generally lower 
than the mean survival for Japan.
Variation in survival between the provinces of Canada 
and the states and territories of Australia was generally 
small, and overall survival was high: this suggests health 
care of a high standard in most areas. Variation between 
the countries of Europe was much wider.
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The substantial diﬀ erences in survival between Australia 
and the UK have been noted before.91 They are unlikely to 
be because of diﬀ erences in data quality. For breast cancer, 
survival from both localised and regional disease was 
higher in Australia, but survival from metastatic disease 
was similar. Elderly women in England had especially poor 
survival. More eﬀ ective treatment in Australia is a plausible 
explanation.92
Comparisons of cancer survival between Europe and the 
USA since 2000 have identiﬁ ed wide diﬀ erences, with 
survival usually higher in the USA.9 Closer assessment of 
these diﬀ erences with more detailed data, not routinely 
collected by all registries, has enabled the explanatory eﬀ ect 
of clinical variables such as stage at diagnosis, investigative 
approach, anatomical site, and morphology to be quantiﬁ ed 
for colorectal cancer12,93 and breast cancer,10 and for a range 
of cancers in children.11 In those studies, the USA has 
always been represented by data from the SEER Program 
registries, representing some 10% of the US population at 
that time, because no other data have been available. The 
availability of data from a large number of state-wide 
population-based cancer registries that began oper ation 
around 1990, and meet data quality standards comparable 
with those of the SEER registries, now enables a larger 
proportion of the US population to be included in national 
and international comparisons of cancer survival. The 
CONCORD study provided the ﬁ rst opportunity for 
the cancer registries of 11 US states in the NPCR to follow 
up all their patients for vital status and to undertake 
analyses of cancer survival, and 42% of the US population 
is included in these analyses.
The survival diﬀ erences between US and European 
patients with cancer, especially in the oldest patients, seem 
unlikely to be attributable to artefacts of cancer registration. 
The CONCORD study has nonetheless identiﬁ ed two 
methodological issues that probably do explain some of 
the well-known diﬀ erences in survival between Europe 
and the USA, from which only SEER data have been 
available until now.
First, relative survival was about 2–4% higher in SEER-9 
areas than in participating NPCR areas of the USA. 
Consequently, cancer survival in the 42% of the US 
population covered by the CONCORD study was 1–3% 
lower than survival in the SEER areas alone (10% of the 
US population). Direct estimation of cancer survival for 
other areas of the USA would be desirable.
Second, census-derived US national life tables give 
higher estimates of all-cause mortality than are noted in 
the SEER areas, especially with the gradual decline of 
mortality in the decade after a census.46 Use of census-
derived national life tables to estimate relative survival 
(the SEER approach) therefore produces estimates that 
are almost always higher than those obtained with state-
speciﬁ c life tables for each calendar year in the decade 
(CONCORD approach), which we believe to be more 
appropriate because it provides tighter control for 
changes over time in background mortality. With the 
CONCORD approach, age-standardised 5-year survival 
in the 22 participating areas of the USA was up to 3% 
lower than with the SEER approach for breast cancer in 
women, up to 4% lower for colorectal cancer, and up to 
5% lower for prostate cancer (available online34).
The diﬀ erences in cancer survival between blacks and 
whites of both sexes in the USA are large, and remarkably 
consistent in 16 states and six metropolitan areas—more 
populations than it has been possible to study in the past.94 
The diﬀ erences were adjusted for age and for diﬀ erences 
in background mortality between blacks and whites within 
each state or metropolitan area. It would be interesting to 
know if the diﬀ erences were attributable to artefact, or 
diﬀ erences between blacks and whites in tumour biology, 
in stage at diagnosis, in access to health care, or in com-
pliance with treatment. The survival diﬀ erences seen in 
this study are consistent with those in other studies.47–53 
Data-collection systems were identical for all races. The 
black–white diﬀ erences in relative survival that we report 
would have been even larger if we had used race-speciﬁ c 
national life tables instead of race–state life tables, because 
back ground mortality is higher (and expected survival 
lower) in blacks than in whites in all the populations 
studied.23,95
Survival from cancers of the breast, colorectum, and 
prostate varied with the type of health insurance in a 
population-based study:96 survival was highest in patients 
who had private insurance, intermediate with federal 
insurance, and lowest with no insurance. Another study97 
suggested that prostate cancer is not more biologically 
aggressive in blacks than whites. Late stage,98 less treat-
ment, and higher mortality seem to be associated with 
black race, low socioeconomic status, and poor survival in 
the USA.99–101 Extensive reviews have led to the conclusion 
that racial disparities in cancer treatment, which are not 
explained by clinical factors, lead to worse outcomes in 
blacks.102,103 Analysis of SEER data suggested that some 
racial diﬀ erences in treatment and cause-speciﬁ c survival 
persist after adjustment for poverty.104 By contrast, the racial 
diﬀ erence in survival from colorectal cancer was almost 
absent in patients managed under the equal-access, 
integrated health-care Veterans’ Aﬀ airs system.105 Finally, 
overviews of race, socioeconomic status, and cancer 
outcomes strongly suggest that equal treatment yields 
equal outcome, irrespective of race.53,106 The data presented 
here extend the evidence that cancer survival in the USA is 
lower in blacks than in whites.
Simple ranking of countries by overall survival can be 
misleading. Survival is very similar in many European 
countries, at the centre of the global range, and a small 
shift in the survival estimate in either direction can entail a 
large change in the rank. Thus, even the national survival 
estimates for Iceland and Malta have wide conﬁ dence 
intervals and unstable rankings because they are based on 
populations of around 250 000 (ﬁ gures 1 and 3). The 
detailed data by country and region are tabulated by 
continent, country, and region, rather than ranked: some 
Articles
752 www.thelancet.com/oncology   Vol 9   August 2008
estimates, based on sparse data, could not be age-
standardised (table 2).
The numbers of patients included in the analysis varied 
widely, as did the proportion of the national population 
covered by the data. These proportions aﬀ ect the extent to 
which the survival estimates can be deemed representative 
of the country concerned. For example, in Algeria, Brazil, 
and Germany, only 1–4% of the national populations were 
covered by the data. Population coverage of participating 
registries in Italy was about 15%, but they were concentrated 
in the wealthier north of the country.22,30 The same point 
also applies to the USA, however, because the data pre-
sented here conﬁ rm suggestions107 that cancer survival in 
the SEER Program areas (10% population coverage during 
the 1990s) was higher than in other parts of the country. By 
contrast, regional variation in survival in Australia and 
Canada was much less marked than in the USA. Similarly, 
survival for 1990–94 in the four French départements 
reported here (6% national coverage) was high on the 
European scale for most cancers,27 and a much larger study 
for the same period in 14 départements (20% coverage) 
showed similar patterns of survival.108,109
For countries with more than one contributing registry 
but less than 100% population coverage, we have 
presented estimates of survival derived from the pooled 
data, not weighted means of the regional estimates of 
survival. The question of whether pooled survival esti-
mates derived from regional registries with less than 
100% national coverage can properly be considered 
representative of cancer survival in the whole country has 
been discussed else where.22 If population-based estimates 
of cancer survival are deemed reliable, however, they do 
suggest a poten tially achievable level of survival, irrespec-
tive of whether the estimate is for a whole country or only 
one region in that country. Regional variation in survival 
within a country tends to prompt eﬀ orts to improve 
survival in regions where it is low. The same argument 
should apply on an inter national scale. This has already 
happened in Europe.110
No overall worldwide estimate for cancer survival has 
been presented. The proportionate contributions from 
each continent to the CONCORD study are very diﬀ erent 
from the worldwide distribution of cancers of the breast, 
colon, rectum, and prostate. The national data for Australia 
alone represented 63% of the population of Oceania in 
1995,111 and the survival estimates for North America 
included 44% of the combined populations of USA and 
Canada around 1992, but for Africa, Asia, and South 
America, the population coverage of these data was much 
lower. The survival data for Europe were based on 25% of 
the continental population of 512 million in 1992,112 but the 
EUROCARE study (ongoing since 1989) is the largest and 
most widely cited international study of cancer survival, 
and all 57 cancer registries in that study, and six others, 
contributed to CONCORD. To provide an international 
summary measure of cancer survival for visual comparison, 
we therefore used the overall estimates for 23 countries in 
EUROCARE-3, but age-standardised to the ICSS weights 
used in CONCORD, instead of the weights used in 
EUROCARE-3.113 We have presented pooled estimates of 
survival for Europe and North America (table 3), but not 
for other continents.
The size of the population covered by the data aﬀ ects the 
statistical precision of the survival estimates. This is 
shown by 95% CIs, but ranked graphics do not provide 
visual appreciation of the extent to which the survival 
estimate for a given country or region falls outside the 
distribution of survival estimates that might be expected, 
under the hypothesis that survival should be the same in 
all areas. In that situation, regional variation in relative 
survival should arise only from random variation around 
some underlying average. We used funnel plots62 to 
provide that visual eﬀ ect for geographical and racial 
variation in survival in the USA, with the target value as 
the pooled estimate for the USA, age-standardised to the 
ICSS weights.60 These plots display striking geographical 
and racial variation in survival.
Clinical practice has continued to evolve in the 15 years 
or so since the patients included in this study were 
diagnosed. Changes in diagnosis, screening, and treatment 
have undoubtedly improved the prognosis for cancer 
patients, at least in wealthier countries.
Survival has increased substantially for cancers of 
the breast (women), colon, rectum, and prostate in the 
17 areas of the USA covered by the SEER Program during 
1996–2003,114 and in Canada (1996–98)115 and Australia 
(1994–2004).116,117 Smaller increases have been reported in 
11 of the 47 Japanese prefectures.118 These estimates of 
relative survival, published for national purposes, cannot 
be compared with the data reported here, however, because 
of diﬀ erences in the quality control of incidence data or 
completeness of follow-up, and in methods of analysis. 
Some estimates were not age-standardised for international 
comparison, whereas others were standard ised to country-
speciﬁ c age weights, rather than the ICSS age weights that 
we used.
The only recent international study of cancer survival is 
EUROCARE-4, which included patients diagnosed in 
23 countries during all or part of 1995–2002 and followed 
up to 2003.29,30 Survival increased substantially in eastern 
European countries, where it was much lower than in 
other parts of Europe during 1990–94. This narrowing of 
the east–west gap suggests substantial improvements in 
cancer care. The rise in breast cancer survival in several 
countries was associated with a fall in mortality, possibly 
because of improved care and screening programmes; the 
rise in prostate-cancer survival (and incidence) might be a 
result of more widespread PSA testing. In western Europe, 
survival in the UK and Denmark was still low for several 
cancers in the late 1990s.
CONCORD is, by chance, reasonably well-timed to 
provide a baseline for international comparisons of 
cancer survival to assess the eﬀ ect of several major 
public health initiatives for the control of breast, 
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colorectal, and prostate cancers. In 1990, mass 
population screening for breast cancer with 
mammography was beginning in many (but not all) 
participant countries. At that time, intense early 
diagnostic activity with prostate-speciﬁ c antigen (PSA) 
had recently become widespread in the USA, but was 
little used elsewhere. In Denmark, for example, the 50-
year increase in prostate cancer incidence is considered 
real,119 but the Danish Society for Urology assessed the 
evidence in 1990120 and decided not to advocate PSA 
testing in asymptomatic men, because the therapeutic 
beneﬁ t was very small;121 only sympto matic patients 
were oﬀ ered treatment. Mass screening for colorectal 
cancer with faecal occult blood (FOB) testing or 
endoscopy had not begun during 1990–94 in any 
contributing country as far as we are aware. Opportunistic 
screening with the FOB test began in Japan in 1992; by 
2004, about 20% of people aged 40 years or over had 
been tested within the previous year.122 Opportunistic 
endoscopy had already become widespread in some 
parts of the US population by 1990.
The CONCORD study was planned in three phases. The 
study reported here (phase I, low resolution) was designed 
to quantify international diﬀ erences in population-based 
relative survival by age, sex, country, or region for patients 
diagnosed during 1990–94 with a cancer of the breast, 
colon, rectum, or prostate. Phase II (high resolution) was 
designed to help interpret those international diﬀ erences 
in survival, by use of a subset of registries that could re-
abstract detailed clinical data, including stage at diagnosis 
and treatment, from the original medical records for large 
random samples of patients diagnosed with one of the 
same cancers during 1996–98. Findings will be reported in 
due course. Phase III was designed as a blinded, expert 
review of the pathological diagnosis for a subset of patients 
from the phase II study, to assess the extent to which 
international survival diﬀ erences might be attributable to 
diﬀ erences in the pathological deﬁ nition of disease in 
participating countries.
The range of survival estimates for each cancer is very 
wide. Population-based cancer registries are increasingly 
important in the comparative assessment of cancer 
outcomes,123 and even allowing for diﬀ erences in data 
quality or statistical robustness, there is little doubt that the 
chances of survival after a cancer diagnosis vary hugely on 
a global scale.
The comparability of cancer survival estimates between 
countries is criticised far more often than the comparability 
of cancer incidence data from the same registries. There is 
no statistical basis for this distinction. National sensitivities 
about cancer survival seem to be much greater than 
sensitivities about cancer incidence. Cancer survival is a 
measure of the overall eﬀ ectiveness of cancer treatment 
services, whereas cancer incidence is a measure of the 
long-term eﬀ ect of prevention policies, which are less 
visible on a day-to-day basis and can, incorrectly, be seen as 
less important.
Cancer survival is a valuable indicator for international 
comparison of progress in cancer control,76,124,125 despite the 
fact that part of the variation in cancer survival identiﬁ ed in 
this study could be attributable to diﬀ erences in the 
intensity of diagnostic activity (case-ﬁ nding) in participating 
populations. Notably, the very same point applies to 
international comparisons of cancer incidence. If over-
diagnosis—which depends on diagnostic intensity—is 
more marked in one country than another, then it will 
certainly be harder for researchers to compare incidence, 
mortality, and survival in those countries. But over-diag-
nosis has diﬀ erent connotations for health-care systems 
and patients. In each country, the health-care system will 
have to be funded, staﬀ ed, and equipped to cope with the 
diagnostic and therapeutic burden of all patients with 
cancer, however they are diagnosed. The health-care 
system must make provision accordingly, and monitor the 
outcome of that provision; cancer survival is one such 
overall indicator.
Furthermore, a patient with cancer is still a patient with 
cancer, whether or not they represent over-diagnosis. If it 
were possible to distinguish the one from the other reliably, 
it would be done routinely. As it is, a cancer diagnosis 
represents the best that medicine has to oﬀ er in a given 
country at a given time, and that best is variable. PSA 
testing for prostate cancer is an example. No matter how a 
patient with cancer is diagnosed, they have to cope with 
the consequences, both psychological and physical, and 
will usually want to be treated. Such patients cannot be 
excluded from either incidence or survival analyses. We do 
not know who they are. In this sense, cancer incidence and 
survival estimates describe as accurately as possible the 
occurrence and the outcome, respectively, of cancer as it is 
diagnosed and treated at a given time in a given 
population.
Most of the wide global range in survival is probably 
attributable to diﬀ erences in access to diagnostic and 
treatment services.3,82,89,91,126 International variation in 
survival in Europe has been associated with national levels 
of economic development, as measured by total national 
expenditure on health.29 Survival is positively associated 
with gross domestic product and the amount of investment 
in health technology such as CT scanners.124 Part of the 
international variation in survival is thus probably 
attributable to under-investment in health resources.127,128 
The variation in survival might be considered intuitively 
obvious, given wide global variation in expenditure on 
health care, whether that is expressed in absolute terms or 
as a proportion of national resources. A parallel could be 
drawn with diﬀ erences in survival between rich and poor 
patients with cancer in a given country, which have 
frequently been reported.129,130
Until now, however, direct international comparisons of 
cancer survival between high-income and low-income 
countries have not generally been available. The infor-
mation provided here might therefore be a useful stimulus 
for change.
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